

# MSNT MSNT & ASSOCIATES LLP

CHARTERED ACCOUNTANTS CHARTERED ACCOUNTANTS

## Independent Auditor's Report on Restated Consolidated Financial Statements

To  
**The Board of Directors**  
**Chandan Healthcare Limited**  
Biotech Park, Sector G, Kursi road, Jankipuram  
Lucknow, Uttar Pradesh, India, 226021

Dear Sir,

1. We have examined the attached restated consolidated financial information of **CHANDAN HEALTHCARE LIMITED** (hereinafter referred to as "**the Company**") and its subsidiaries (the Company and its subsidiaries collectively referred to as the "**Group**") comprising the Restated Consolidated Statement of Assets and Liabilities as at December, 31 2024, March 31, 2024, March 31, 2023 and March 31, 2022, the Restated Consolidated Statements of Profit and Loss, the Restated Consolidated Cash Flow Statement for nine month ended December, 31 2024 and the year ended March 31, 2024, March 31, 2023, March 31, 2022, the Statement of Significant Accounting Policies and the Notes as forming part of these Restated Consolidated Financial Statements (collectively, the "**Restated Consolidated Financial Information**"), as approved by the Board of Directors of the Company at their meeting held on 30<sup>th</sup> January, 2025, for the purpose of inclusion in the Red Herring Prospectus/ Prospectus ("Offer Document") prepared by the Company in connection with its proposed SME Initial Public Offer.

These Restated Summary Statements for offer of equity shares ("**SME IPO**") has been prepared in accordance with the requirements of:

- (i) sub-clauses (i) and (iii) of clause (b) of sub-section (1) of section 26 of part I of chapter III of the Companies Act, 2013 including Rules thereon, as amended ("**the Act**") read with Companies (Prospectus and Allotment of Securities) Rules 2014;
- (ii) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended ("**ICDR Regulations**") and related amendments / clarifications from time to time issued by the Securities and Exchange Board of India ("**SEBI**")
- (iii) The Guidance Note on Reports in Company Prospectus (Revised 2019) issued by the Institute of Chartered Accountants of India ("**ICAI**"), as amended from time to time (the "**Guidance Note**")

2. In terms of Schedule-VI of the SEBI (ICDR) Regulations, 2018 and other provisions relating to accounts, We, **M/s M S N T & Associates LLP.**, Chartered Accountants, have been subjected to the peer review process of the Institute of Chartered Accountants of India (ICAI) and hold valid **Certificate No. 013922** dated 03 January 2022 issued by the "Peer Review Board" of the ICAI.

📍 : **Head Office:** - A-40, I-Thum, Tower-B, 10<sup>th</sup> Floor, Unit No. 1033, Sector 62, Noida-201305.  
**Branch Office:** - SEJ Plaza – Second Floor, Office No S34, Marve Road, Above N M Medical  
Near Nutan School, Off S V Road, Malad (W), Mumbai-400064.  
**Branch Office:** - A-504, Ansal Chamber-1, Bhikaji Cama Place, New Delhi-110066.



3. The Company's Board of Directors are responsible for the preparation of the Restated Consolidated Financial Information for the purpose of inclusion in the Offer Document to be filed with Securities and Exchange Board of India, relevant stock exchange and Registrar of Companies, Kanpur in connection with the proposed SME IPO. The Restated Consolidated Financial Information has been extracted by the management from the Audited Financial Statements of the group for the period ended 31<sup>st</sup> December, 2024, 31<sup>st</sup> March, 2024, 31<sup>st</sup> March, 2023 and 31<sup>st</sup> March 2022, which have been approved by the Board of Directors of the respective companies with in the group. The Board of Directors responsibility includes designing implementing and maintaining adequate internal control relevant to the preparation and presentation of the Restated Consolidated Financial Information. The Board of Directors is also responsible for identifying and ensuring that the Company complies with the Companies Act, (ICDR) Regulations and the Guidance Note.
4. We have examined such Restated Consolidated Financial Information taking into consideration:
  - i. The terms of reference to our engagements with the Company letter dated 4<sup>th</sup> April 2024 requesting us to carry out the assignment, in connection with the Red Herring Prospectus/Prospectus being issued by the Company for its proposed Initial Public Offering of equity shares in SME Platform of relevant stock Exchange. ("IPO" or "SME IPO").
  - ii. The Guidance Note. The Guidance Note also requires that we comply with the ethical requirements of the Code of Ethics issued by the ICAI.
  - iii. Concepts of test checks and materiality to obtain reasonable assurance based on verification of evidence supporting the Information; and Restated Consolidated Financial Information; and
  - iv. The requirements of Section 26 of the Act and the ICDR Regulations

Our work was performed solely to assist you in meeting your responsibilities in relation to your compliance with the Act, the ICDR Regulations and the Guidance Note in connection with the IPO. We have audited such consolidated financial information of the company for the limited purpose of complying with the requirement of getting its financial statements audited by an audit firm holding a valid peer review certificate issued by the "Peer Review Board" of the ICAI as required by ICDR Regulations in relation to proposed IPO. We have issued our report dated 30<sup>th</sup> January 2025 on these consolidated financial information to the Board of Directors who have approved these in their meeting held on 30<sup>th</sup> January 2025.

5. In accordance with the requirements of the Act including the rules made there under, ICDR Regulations, Guidance Note and Engagement Letter, we report that:
  - (i) The "**restated statement of consolidated asset and liabilities**" of the Company as at December 31, 2024, March 31, 2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.
  - (ii) The "**restated statement of Consolidated profit and loss**" of the Company for the nine month ended 31<sup>st</sup> December, 2024 and for the year ended on March 31,



2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.

(iii) The “**restated statement of consolidated cash flows**” of the Company for the nine month ended 31<sup>st</sup> December, 2024 and for the year ended on March 31, 2024, March 31, 2023, and March 31, 2022 examined by us, as attached to this report read with significant accounting policies has been arrived at after making such adjustments and regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate.

6. Based on our examination, we are of the opinion that the restated consolidated financial statements have been prepared after incorporating:

- a) Regroupings to the audited consolidated financial statements of the Company, as in our opinion were appropriate
- b) There are no adjustments for the changes in accounting policies retrospectively in respective financial years to reflect the same accounting treatment as per the changed accounting policy for all reporting periods, if any.
- c) There are no adjustments for prior period and other material amounts in the respective financial year to which they relate and there are no qualifications which require adjustments and
- d) There are no extra-ordinary items that need to be disclosed separately in the accounts and qualifications requiring adjustments
- e) There were no qualifications in the Audit Reports issued by the Statutory Auditors for the nine month ended 31<sup>st</sup> December, 2024 and for the financial year ended on 31<sup>st</sup> March 2024, 2023, and 2022 which would require adjustments in this Restated Financial Statements of the Company.
- f) These Profits and Losses have been arrived at after charging all expenses including depreciation and after making such adjustments/restatements in respect of regroupings as in our opinion are appropriate and are to be read in accordance with the Significant Accounting Policies and Notes to Accounts as set out in attachment to this report.

7. Audit of **CHANDAN HEALTHCARE LIMITED** for the nine month ended 31<sup>st</sup> December, 2024 and for the year ended 31<sup>st</sup> March 2024 & 31<sup>st</sup> March 2023 is Conducted by us. whereas audit for the financial year ended 31<sup>st</sup> March 2022 was conducted by M/s Ashish Mishra & Associates and accordingly reliance has been placed on the financial information examined by them for the said year.

8. We have also examined the following other financial information relating to the Company prepared by the Management and as approved by the Board of Directors of the Company and annexed to this report relating to the Company for the nine month ended 31<sup>st</sup> December, 2024 and for the year ended 31<sup>st</sup> March 2024, 31<sup>st</sup> March 2023 and 31<sup>st</sup> March 2022 proposed to be included in the Offer Document.



9. We conducted the audit of Chandan Pharmacy Ltd, one of the three subsidiaries. However, we did not audit the financial statements of the other two subsidiaries, Chandan Diagnostic Limited and Indira Diagnostic Centre & Blood Bank Limited, whose share of profit has been included in the consolidated financial information. The financial statements of these subsidiaries have been audited by other auditors, and their reports have been provided to us by the Company's management. Our opinion on the consolidated financial statements, as it pertains to the amounts and disclosures related to these components, is based solely on the reports of the other auditors:

(Rs in Lakhs)

Particulars	For the nine-month ended December 31, 2024	for the year ended March 31, 2024	for the year ended March 31, 2023	for the year ended March 31, 2022
Number of subsidiaries	3	3	3	3
Revenue of subsidiaries	7,536.30	7,671.53	6,105.60	4,795.94

10. The Restated consolidated Financial Information do not reflect the effects of events that occurred subsequent to the respective dates of the reports on the audited consolidated financial statements mentioned above.
11. The preparation and presentation of the consolidated Financial Statements referred to above are based on the Audited consolidated financial statements of the Company and are in accordance with the provisions of the Act and ICDR Regulations. The consolidated Financial Statements and information referred to above is the responsibility of the management of the Company.
12. The report should not in any way be construed as a re-issuance or re-dating of any of the previous audit reports issued by any other firm of chartered accountants nor should this report be construed as a new opinion on any of the financial statements referred to therein.
13. We have no responsibility to update our report for events and circumstances occurring after the date of the report.
14. In our opinion, the above consolidated financial information attached to this report read with the respective significant accounting policies and notes to restated statements as attached are prepared after making adjustments and regrouping as considered appropriate and have been prepared in accordance with the Act, ICDR Regulations, Engagement Letter and Guidance Note.



15. Our report is intended solely for use of the Board of Directors for inclusion in the Offer Document in connection with the SME IPO. Our report should not be used, referred to or adjusted for any other purpose except with our consent in writing. Accordingly, we do not accept or assume any liability or any duty of care for any other purpose or to any other person to whom this report is shown or into whose hands it may come without our prior consent in writing.

Yours faithfully,

**For MSNT & ASSOCIATES LLP**

**Chartered Accountants**

**Firm Registration No. 018542C/C400322**



**Navodit Tyagi**

**Partner**

**Membership No.-533375**

**UDIN No:25533375BMOKLO1165**

**Place: Noida**

**Date: 30/01/2025**

Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Profit and loss for the nine months ended 31st December, 2024

Particulars	Note No.	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
I. Revenue from operations	24	16,747.47	17,659.01	13,688.94	11,956.35
II. Other income	25	51.35	136.85	13.98	35.23
<b>III. Total revenue(I+II)</b>		<b>16,798.82</b>	<b>17,795.86</b>	<b>13,702.92</b>	<b>11,991.58</b>
<b>IV. Expenses:</b>					
Cost of material consumed	26	980.88	1,112.68	1,388.00	967.89
Purchase of stock-in-trade	27	7,114.09	7,236.76	5,493.56	5,332.58
Change in inventories of finished goods,work-in-progress and stock-in-trade.	28	(374.73)	(264.47)	(410.16)	(74.28)
Employee benefits expense.	29	2,914.21	3,537.96	2,549.09	1,872.98
Finance Costs	30	327.99	275.19	241.91	170.62
Depreciation and amortisation expense	14	404.92	340.40	208.95	196.06
Other expenses	31	3,090.97	3,411.34	3,730.45	3,631.76
<b>Total expenses (IV)</b>		<b>14,458.33</b>	<b>15,649.86</b>	<b>13,201.80</b>	<b>12,097.61</b>
<b>V. Profit/(loss) before exceptional &amp; extraordinary items and tax (III-IV)</b>		<b>2,340.49</b>	<b>2,146.00</b>	<b>501.12</b>	<b>(106.03)</b>
VI. Exceptional items		-	-	-	-
<b>VII. Profit/(loss) before extraordinary items and tax (V-VI)</b>		<b>2,340.49</b>	<b>2,146.00</b>	<b>501.12</b>	<b>(106.03)</b>
VIII. Extraordinary items		-	-	-	-
<b>IX. Profit/(loss) before tax (VII- VIII)</b>		<b>2,340.49</b>	<b>2,146.00</b>	<b>501.12</b>	<b>(106.03)</b>
X. Tax expense of continuing operation:-					
Current tax		539.60	510.57	111.31	3.23
Deferred tax		58.90	(0.07)	31.18	-
<b>Tax expense(X)</b>		<b>598.50</b>	<b>510.50</b>	<b>142.49</b>	<b>3.23</b>
<b>XI. Profit/(loss) for the period from continuing operations(after tax) (IX-X)</b>		<b>1,741.99</b>	<b>1,635.50</b>	<b>358.63</b>	<b>(109.26)</b>
XII. Profit/(loss) from discontinuing operations		-	-	-	-
XIII. Tax expense of discontinuing operations		-	-	-	-
<b>XIV. Profit/(loss) from discontinuing operations (after tax) (XII-XIII)</b>		<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV. Share of (profit)/ loss transferred to minority interest		(127.07)	(7.85)	(21.83)	(1.64)
<b>XVI. Profit/ (Loss) after tax attributable to owners of the company (XI+XIV+XV)</b>		<b>1,614.92</b>	<b>1,627.65</b>	<b>336.80</b>	<b>(110.90)</b>
XVII. Earnings per equity share:					
(1) Basic		8.07	8.14	1.68	(0.55)
(2) Diluted		8.07	8.14	1.68	(0.55)

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msnt & Associates LLP

Chartered accountants

Firm registration no. :- 018542C/C400322

Navodit Tiagi  
Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKLO1165

Place :- Noida

Date :- 30th Jan 2025



For & on behalf of the board of directors

Chandan Healthcare Limited

Amar Singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 30th Jan 2025

Rajeev nain

CFO & Company secretary

Place :- Lucknow

Date :- 30th Jan 2025



Asmita Singh

Director

Din. :- 01098055

Place :- Lucknow

Date :- 30th Jan 2025



Company name :- Chandan Healthcare Limited  
CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Balance sheet as at 31st December, 2024

Particulars	Note No.	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>I. EQUITY AND LIABILITIES</b>					
(1) Shareholder's funds					
(a) Share capital	3	2,000.00	2,000.00	2,000.00	2,000.00
(b) Minority interest	4	373.09	246.02	238.17	216.34
(c) Reserves and surplus	5	3,430.99	2,116.07	736.87	400.07
(c) Money received against share warrants	-	-	-	-	-
(2) Share application money pending allotment	-	-	-	-	-
(3) Non-current liabilities					
(a) Long-term borrowings	6	1,974.05	1,217.56	789.04	670.08
(b) Deferred tax liabilities(net)	7	198.25	139.36	139.43	108.25
(c) Other long-term liabilities	8	0.45	0.45	0.65	0.65
(d) Long term provisions	9	326.54	305.75	218.41	215.92
(4) Current liabilities					
(a) Short-term borrowings	10	3,218.27	2,983.71	1,346.46	988.09
(b) Trade payables	11				
(i) Total outstanding dues of micro & small enterprises.		531.57	626.71	337.45	144.13
(ii) Total outstanding dues of creditors other than micro & small enterprises.		3,817.66	1,517.35	3,156.74	2,515.54
(c) Other current liabilities	12	880.20	1,558.91	768.02	819.21
(d) Short term provisions	13	255.19	174.49	51.26	44.47
<b>TOTAL</b>		<b>17,006.26</b>	<b>12,886.38</b>	<b>9,782.50</b>	<b>8,122.76</b>
<b>II. ASSETS</b>					
(1) Non-current assets					
(a) Property, plant & equipments & intangible assets	14				
(i) Property, plant & equipments		6,461.11	4,406.12	2,812.34	2,493.35
(ii) Intangible assets		443.27	443.27	443.27	443.27
(iii) Capital work in progress					
(iv) Intangible assets under development					
(b) Non-current investments	15	337.72	337.72	422.52	579.91
(c) Deferred tax assets(net)	-	-	-	-	-
(d) Long-term loans and advances	16	603.31	121.60	393.91	131.99
(e) Other non-current assets	17	189.44	362.16	355.11	159.15
(2) Current assets					
(a) Current investments	18	-	-	286.17	-
(b) Inventories	19	3,127.55	1,824.37	987.12	656.03
(c) Trade receivables	20	3,951.99	2,656.05	2,368.84	2,869.81
(d) Cash and bank balances	21	1,042.54	524.64	204.46	157.63
(e) Short-term loans and advances	22	781.98	2,149.29	1,490.82	621.13
(f) Other current assets	23	67.35	61.16	17.94	10.48
<b>TOTAL</b>		<b>17,006.26</b>	<b>12,886.38</b>	<b>9,782.50</b>	<b>8,122.76</b>

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached  
For M/s Ment & Associates LLP  
Chartered accountants  
Firm registration no. :- 018542C/C400322

Navodit tyagi  
Partner  
Membership no. :- 533375  
UDIN no. :- 25533375BMOKLO1165  
Place :- Noida  
Date :- 30th Jan 2025



For & on behalf of the board of directors  
Chandan Healthcare Limited

Amar singh  
Managing director  
Din. :- 01096328  
Place :- Lucknow  
Date :- 30th Jan 2025

Rajeev nain  
CFO & Company Secretary  
Place :- Lucknow  
Date :- Lucknow



Smrita singh  
Director  
Din. :- 01098055  
Place :- Lucknow  
Date :- 30th Jan 2025



Company name :- Chandan Healthcare Limited

CIN :- U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Cash flow statement for the nine month ended 31st December, 2024

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
<b>A. Cash flow arising from operating activities</b>				
Profit / (Loss) before tax	2,340.49	2,146.00	501.12	(106.03)
<b>Adjustments related to non-cash &amp; non operating transactions:</b>				
<b>Non cash transactions</b>				
Depreciation & amortisation of fixed assets	404.92	340.40	208.95	196.06
Bad Debts & Balances written off/written back	9.64	3.52	3.89	520.78
Preliminary expenses written off	-	-	-	-
Re-measurement (gains) / loss on defined benefit plans	62.90	89.77	102.87	85.36
Provision for doubtful debts	15.43	5.24	-	-
Provision for obsolete inventories	24.49	6.26	-	-
Loss(gain) on account of foreign exchange fluctuations	-	-	-	-
Other non-cash transactions(specify nature)	-	-	-	-
<b>Non operating transactions</b>				
Interest on borrowing	315.06	260.72	231.32	160.95
Loss/(profit) on the sale of property, plant & equipments & intangible assets	-	-	-	-
Loss/(profit) on the sale of investments	-	-	-	-
Interest income	(42.41)	(24.50)	(7.75)	(5.86)
Dividend income	-	(75.98)	-	(7.16)
Other non-operating transactions(specify nature)	-	-	-	-
<b>Operating profit/(loss) before working capital changes</b>	<b>3,130.52</b>	<b>2,751.42</b>	<b>1,040.39</b>	<b>844.09</b>
<b>Adjustment for change in working capital:</b>				
(Increase) / Decrease in inventories	(1,327.67)	(843.51)	(331.09)	(45.01)
(Increase) / Decrease in trade receivables	(1,321.01)	(295.98)	497.10	(1,037.44)
(Increase) / Decrease in other current assets	1,052.13	(436.44)	(1,335.02)	(317.59)
(Decrease) / Increase in trade paybles	2,205.17	(1,350.13)	834.52	747.45
(Decrease) / Increase in other current liabilities	(678.71)	911.49	(144.80)	430.30
<b>Net cash (used in) / generated from operating activities</b>	<b>3,060.43</b>	<b>736.85</b>	<b>561.10</b>	<b>621.79</b>
Income taxes refund / (paid), net	(501.02)	(490.54)	(111.32)	(11.81)
<b>Net cash flow from operating activities(A)</b>	<b>2,559.41</b>	<b>246.31</b>	<b>449.78</b>	<b>609.98</b>
<b>B. Cash flow arising from investing activities</b>				
Sale/(Purchase) of tangible and intangible assets	(2,459.91)	(1,954.19)	(527.94)	(664.19)
Sale/(Purchase) of non current & current investments	-	370.97	(128.77)	(423.55)
Interest income	42.41	24.50	7.75	5.86
Dividend income	-	75.98	-	7.16
Other income	-	-	-	-
<b>Net cash flow from investing activities(B)</b>	<b>(2,417.50)</b>	<b>(1,482.73)</b>	<b>(648.96)</b>	<b>(1,074.72)</b>
<b>C. Cash Flow Arising From Financing Activities</b>				
Proceeds from issuance of share capital	-	-	-	474.00
Proceeds from/(Payment of) long term & short term borrowings	991.05	2,065.77	477.33	149.69
Finance cost paid (including processing fees)	(315.06)	(260.72)	(231.32)	(160.94)
Dividend paid	(300.00)	(248.45)	-	(115.00)
<b>Net cash flow from financing activities(C)</b>	<b>375.99</b>	<b>1,556.60</b>	<b>246.01</b>	<b>347.75</b>
<b>Net increase/decrease in cash or cash equivalents(A+B+C)</b>	<b>517.90</b>	<b>320.18</b>	<b>46.83</b>	<b>(116.99)</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>524.64</b>	<b>204.46</b>	<b>157.63</b>	<b>274.62</b>
<b>Cash and cash equivalents at the end of the period</b>	<b>1,042.54</b>	<b>524.64</b>	<b>204.46</b>	<b>157.63</b>

Significant accounting policies and notes to financial statements.

The notes referred to above form an integral part of the balance sheet.

As per our report of even date attached

For M/s Msmt & Associates LLP

Chartered accountants

Navodit tyagi

Partner

Membership no. :- 533375

UDIN no. :- 25533375BMOKLO1165

Place :- Noida

Date :- 30th Jan 2025



For & on behalf of the board of directors

Chandan Healthcare Limited

Amar Singh

Managing director

Din. :- 01096328

Place :- Lucknow

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025



Asmita Singh

Director

Din. :- 01098055

Place :- Lucknow

Date :- 30th Jan 2025



Rajeev nain

CFO & Company Secretary

Place :- Lucknow

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025

Date :- 30th Jan 2025



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

**Note No. :- 1 : Corporate information**

Chandan Healthcare Limited, established on September 3, 2003, specializes in operating state-of-the-art laboratories that offer comprehensive pathological investigations. Our services encompass biochemistry, hematology, histopathology, microbiology, and immunology. Additionally, we provide an extensive array of radiology services, including CT scans, X-rays, and MRIs. Committed to accuracy and reliability, Chandan Healthcare supports healthcare professionals and patients by delivering essential diagnostic services.



(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

**Note No. :- 2 : Summary of Significant accounting policies**

**a) Basis of Preparation of Financial Statements**

The financial statements have been prepared in accordance with the historical cost convention, accrual basis, and going concern assumption, as mandated by generally accepted accounting principles (GAAP) in India. GAAP encompasses the mandatory accounting standards specified under Section 133 of the Companies Act, 2013, in conjunction with Rule 7 of the Companies (Accounts) Rules, 2014, and the relevant provisions of the Act (to the extent notified).

Accounting policies have been applied consistently throughout, except where the initial adoption of a new accounting standard or a revision to an existing accounting standard necessitates a change in the previously applied accounting policy.

The financial statements are prepared in accordance with Schedule III of the Companies Act, 2013, which significantly influences their disclosure and presentation. Comparative figures for the previous year have been regrouped or reclassified, as necessary, to align with the current year's classification and disclosure requirements.

**b) Use of Estimates**

The preparation and presentation of financial statements necessitate the use of estimates and assumptions that impact the reported amounts of assets, liabilities, and contingent liabilities as of the financial statement date, as well as the reported revenues and expenses for the reporting period. Any variances between actual results and estimates are recognized in the period in which they become known or materialize.

Accounting estimates are subject to periodic revisions, and actual results may differ from these estimates. Adjustments to estimates are made when management becomes aware of changes in the circumstances affecting the estimates. Such changes are reflected in the financial statements for the period in which they occur, and their impact is disclosed in the notes to the financial statements if deemed material.

**c) Functional and presentation currency**

These standalone financial statements are presented in Indian Rupees (Rs.), which is also the Company's functional currency. All amounts have been rounded to the nearest lakhs, unless otherwise indicated.

**d) Current and non-current classification:**

The Company classifies an asset as current when:

- it expects to realise the asset, or intends to sell or consume it, in its normal operating cycle;
- it expects to realise the asset within twelve months after the reporting period;
- it holds the asset primarily for the purpose of trading; or
- the asset is cash or cash equivalent unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non current.

A liability is classified as a current when

- it is expected to be settled in the Company's normal operating cycle;
- the liability is due to be settled within twelve months from the reporting period;
- it is held primarily for the purposes of being trading;
- it does not hold an unconditional right to defer settlement of the liability for at least twelve months after the reporting period. Terms of a liability that could, at the option of the counter party, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

The operating cycle is the time between the acquisition of assets for processing and realisation in cash or cash equivalents. The Company's normal operating cycle is twelve months.



**e) Significant accounting policies**

**i.) Revenue recognition**

Revenue from the **sale of goods** is recognized when ownership, along with all significant risks and rewards, has been transferred to the customer. Revenue from the **sale of services** is recognized using the **completed service contract method**, provided there are no significant risks and rewards associated with the contract. Sales are accounted for net of amounts recovered towards GST and sales returns.

Sales returns are recorded upon the actual receipt of returned goods or the settlement of claims.

Revenue arising from the use by others of enterprise resources yielding interest and dividends should only be recognized when the right to receive payment is established.

**Interest:** On a time proportion basis taking into account the amount outstanding and the rate applicable.

**Dividends:** When the owner's right to receive payment is established.

**ii.) Inventories**

Inventories comprise of diagnostic kits, reagents, laboratory chemicals and consumables, these are measured at cost less accumulated impairment loss, if any.

**iii.) Property, plant & equipments**

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that the cost can be measured reliably. The cost of an item of property, plant and equipment comprises its purchase price, including non refundable purchase price and other costs directly attributable to bringing the asset to the location and condition necessary for it to be available for use. The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, including the cost of services rendered by employees of the Company. Any gain or loss on disposal of an item of property, plant and equipment is recognised in profit or loss.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the disposal of the asset.

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company and the cost of the item can be measured reliably.

**iv.) Intangible assets**

Intangible assets that are acquired, are recognized at cost initially and carried at cost less accumulated amortization and accumulated impairment loss, if any. Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates.



#### **v.) Depreciation & Amortisation**

Depreciation is recognised so as to write off the cost of assets (other than freehold land) less their residual values. The Company has charged depreciation on property, plant & equipment (PPE) based on the Straight line. Amortisation is calculated to write off the cost of intangible assets less their estimated residual values over their useful lives. Depreciation and amortisation on additions and deletions are restricted to the period of use. Residual value is considered to be 5% on all the assets. Assets costing below Rs. 5,000 are depreciated using depreciation rate at 100%. Depreciation and amortisation methods, useful lives and residual values are reviewed at each reporting date and

#### **vi.) Employee benefits**

##### **Short-term employee benefits**

Short term employee benefits are measured on an undiscounted basis and expensed as the related service is provided.

##### **Defined contribution plans**

A defined contribution plan is a post-employment benefit plan where the company's legal or constructive obligation is limited to the amount of contributions payable to a fund or plan.

##### **Defined benefit plans**

A defined benefit plan is a post-employment benefit plan other than a defined contribution plan. The company has a defined benefit plan for its employees.

#### **vii.) Lease**

Lease contracts entered by the company majorly pertain to buildings taken on operating lease to conduct its operations.

#### **viii.) Impairment of assets**

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount.



**ix.) Investments**

Current Investments are carried at lower of cost and market value computed Investment wise. Long Term

**x.) Income-tax**

Provision for income tax is made on the basis of taxable income for the year at current rates. Tax expense The deferred tax asset is recognised and carried forward only to the extent that there is a reasonable certainty that Minimum Alternate Tax (MAT) paid in a year is charged to the statement of profit and Loss as current tax. The

**xi.) Provision, contingent liabilities and contingent assets**

A **provision** is recognised when the company has a present obligation (legal or constructive) as a result of past **Contingent liability** is a possible obligation arising from past events and whose existence will be confirmed only by **Contingent assets** are neither recognised nor disclosed in the financial statements, since this may result in the Provisions, contingent liabilities and contingent assets are reviewed at each balance sheet date.

**xii.) Earnings per share**

**Basic Earnings per share**


Basic Earnings Per Share ('EPS') is calculated by dividing the profit attributable to the equity shareholders of the

**Diluted Earnings per share**

Diluted earnings per share is computed by dividing the profit (considered in determination of basic earnings per

**xiii.) Cash flow statement**

Cash flows are reported using the indirect method, whereby profit for the year is adjusted for the effects of



**xiv.) Cash and cash equivalents**

Cash and cash equivalents in the balance sheet and cash flow statement consists of cash on hand, deposits held

**xv.) Dividend**

The company recognises a liability for any dividend declared but not distributed at the end of the reporting period,

**xvi.) Related parties transactions**

The company has a policy to recognize and identify related party transactions; disclosures of related party

**xvii.) Foreign Currency Transactions**


Foreign exchange transactions are recorded at the rates prevailing on the date of transactions. Exchange rate

**xviii.) Borrowing Costs**

Borrowing costs that are attributable to acquisition, construction or production of qualifying assets are capitalised

**xix.) Events after reporting date**

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 3 : Share capital

a. Information on authorised, issued, subscribed and paid-up shares

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Authorised</b>				
Equity shares with voting rights (Current year : 25000000 equity shares of Rs.10/- each) (Previous year : 24000000 equity shares of Rs.10/- each)	2,500.00	2,400.00	2,400.00	2,000.00
<b>Total...</b>	<b>2,500.00</b>	<b>2,400.00</b>	<b>2,400.00</b>	<b>2,000.00</b>
<b>Issued</b>				
Equity shares with voting rights (Current year : 20000000 equity shares of Rs.10/- each) (Previous year : 20000000 equity shares of Rs.10/- each)	2,000.00	2,000.00	2,000.00	2,000.00
<b>Total...</b>	<b>2,000.00</b>	<b>2,000.00</b>	<b>2,000.00</b>	<b>2,000.00</b>
<b>Subscribed and fully paid</b>				
Equity shares with voting rights (Current year : 20000000 equity shares of Rs.10/- each) (Previous year : 20000000 equity shares of Rs.10/- each)	2,000.00	2,000.00	2,000.00	2,000.00
<b>Total...</b>	<b>2,000.00</b>	<b>2,000.00</b>	<b>2,000.00</b>	<b>2,000.00</b>



Notes to restated consolidated financial statements.

Particulars	Restated Consolidated figures as at the end of 31st December, 2024			Restated Consolidated figures as at the end of 31st March, 2024			Restated Consolidated figures as at the end of 31st March, 2023			Restated Consolidated figures as at the end of 31st March, 2022		
	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount	No of shares	Paid up value per share	Amount
<i>Equity shares with voting rights, subscribed and fully paid</i>												
Shares outstanding at the beginning of the year	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00
Add: Fresh shares issued during the year	-	-	-	-	-	-	-	-	-	-	-	-
Add: Bonus shares issued during the year	-	-	-	-	-	-	-	-	-	-	-	-
Less: Shares forfeited/bought back during the year	-	-	-	-	-	-	-	-	-	-	-	-
Shares outstanding at the end of the year	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00	200.00	10.00	2,000.00

**b. Rights, preferences and restrictions of different classes of shares including restrictions on the distribution of dividends and the repayment of capital**

**Equity shares with voting rights, subscribed and fully paid**

The shareholders are entitled to receive dividend in proportion to the amount paid up on the equity shares held by them.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive any of the remaining assets of the company after distribution of all preferential amounts. The distribution will be in proportion of the number of shares held by the shareholders.

The company has only one class of shares referred to as equity shares having a par value of Rs. 10/- Each holder of the equity share is entitled to one vote per share.

**As to dividend:**

**As to repayment of capital:**

**As to voting:**





Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to consolidated financial statements.

c. Details of shareholders holding more than 5% shares of the Company

Name of shareholder	Figures as at the end of 31st Dec, 2024			Figures as at the end of 31st March, 2023			Figures as at the end of 31st March, 2022			
	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)	No of shares	Paid up value per share	Percentage (%)	
Equity shares with voting rights, subscribed and fully paid										
<b>Name of shareholder</b>										
- Amar Anita Holdings (India) Private Limited	58.43	10	29.22%	58.43	10	29.22%	58.43	10	29.22%	29.22%
- Amar Singh	23.20	10	11.60%	23.20	10	11.60%	21.20	10	10.60%	10.60%
- Vinay Lamba	15.85	10	7.92%	15.85	10	7.92%	15.85	10	7.92%	7.92%
- Other shareholders*	102.52	10	51.26%	102.52	10	51.26%	104.52	10	52.26%	52.26%
<b>Total...</b>	<b>200.00</b>		<b>100%</b>	<b>200.00</b>		<b>100%</b>	<b>200.00</b>		<b>100%</b>	<b>100%</b>

\*Other shareholders, each holding less than 5% of the total shares, are included here to ensure reconciliation of the total share count with the notes provided above.

d. Disclosure of shareholding of promoters:

As at 31st Dec, 2024

Name of promoter	No of shares at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
<b>Name of promoter*</b>						
-Alok Singh	3.00	-	-	3.00	1.50%	-
-Amar Singh	23.20	-	-	23.20	11.60%	-
-AmarAnita Holdings (India) Pvt Ltd	58.43	-	-	58.43	29.22%	-
-Asmita Singh	1.62	-	-	1.62	0.81%	-
-Shaleen Solanki	9.00	-	-	9.00	4.50%	-
-Vijay Singh	8.99	-	-	8.99	4.50%	-
-Vinay Lamba	15.85	-	-	15.85	7.92%	-

As at 31st March, 2024

Name of promoter	No of shares at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
Equity shares with voting rights, subscribed and fully paid						
<b>Name of promoter*</b>						
-Alok Singh	3.00	-	-	3.00	1.50%	-
-Amar Singh	21.20	2.00	-	23.20	11.60%	9.43%
-AmarAnita Holdings (India) Pvt Ltd	58.43	-	-	58.43	29.22%	-
-Asmita Singh	1.62	-	-	1.62	0.81%	-
-Shaleen Solanki	9.00	-	-	9.00	4.50%	-
-Vijay Singh	8.99	-	-	8.99	4.50%	-
-Vinay Lamba	15.85	-	-	15.85	7.92%	-

As at 31st March, 2023





Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
<b>Equity shares with voting rights, subscribed and fully paid</b>						
<b>Name of promoter*</b>						
-Aast Singh	0.70	-	-	0.70	0.35%	-
-Amaranita Holdings(I)Pvt.Ltd.	58.43	-	-	58.43	29.22%	-
-Amar Singh	21.20	-	-	21.20	10.60%	-
-Amit Srivastava	3.41	-	-	3.41	1.71%	-
-Anant Singh	1.05	-	-	1.05	0.53%	-
-Asmita Singh	1.62	-	-	1.62	0.81%	-
-Brahm Prakash	0.40	-	-	0.40	0.20%	-
-Deepak Kumar Sirohi	1.80	-	-	1.80	0.90%	-
-Jagjeet Singh Kalsi	2.85	-	-	2.85	1.43%	-
-Rajeev Lochan	2.33	-	-	2.33	1.17%	-
-Rajeev Nain	0.27	-	-	0.27	0.14%	-
-Rajesh Srivastava	0.52	-	-	0.52	0.26%	-
-Rajive Kumar	2.27	-	-	2.27	1.13%	-
-R B Kalia	1.55	-	-	1.55	0.78%	-
-Sandeep Kumar Saraswat	3.08	-	-	3.08	1.54%	-
-Shaleen Solanki	9.00	-	-	9.00	4.50%	-
-Shweta Lamba	4.19	-	-	4.19	2.10%	-
-Subodh Kaul	0.80	-	-	0.80	0.40%	-
-Vijay Singh	8.99	-	-	8.99	4.50%	-
-Vikalp Dixit	3.00	-	-	3.00	1.50%	-
-Vikas Lamba	5.00	-	-	5.00	2.50%	-
-Vinay Lamba	15.85	-	-	15.85	7.92%	-
-Vishal Lamba	1.54	-	-	1.54	0.77%	-

As at 31st March, 2022

Name of promoter	No of shares as at the beginning of year	Addition	Deletion	No of shares as at the end of year	% of total shares	% Change during the year
<b>Equity shares with voting rights, subscribed and fully paid</b>						
<b>Name of promoter*</b>						
- Amar Singh	21.20	-	-	21.20	10.60%	-
- AmarAnita Holdings (India) Private Limited	58.43	-	-	58.43	29.22%	-
- Amit Srivastava	3.41	-	-	3.41	1.71%	-
- Asmita Singh	1.62	-	-	1.62	0.81%	-
- Deepak Kumar Sirohi	1.80	-	-	1.80	0.90%	-
- Dharmendra Singh Malik	2.42	-	-	2.42	1.21%	-
- G B Singh	2.18	-	-	2.18	1.09%	-
- Jagjeet Singh Kalsi	2.85	-	-	2.85	1.43%	-
- Rajeev Lochan	2.33	-	-	2.33	1.17%	-
- Rajive Kumar	2.27	-	-	2.27	1.13%	-
- Sandeep Kumar Saraswat	3.08	-	-	3.08	1.54%	-
- Shweta Lamba	4.19	-	-	4.19	2.10%	-
- Vijay Singh	8.99	-	-	8.99	4.50%	-
- Vikalp Dixit	3.00	-	-	3.00	1.50%	-
- Vikas Lamba	5.00	-	-	5.00	2.50%	-
- Vinay Lamba	15.85	-	-	15.85	7.92%	-
- Virender Singh	2.47	-	-	2.47	1.24%	-
- Vishal Lamba	1.54	-	-	1.54	0.77%	-

\*Individuals designated or to be designated by the company as promoters in its annual return.

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 4 : Minority Interest

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022	
	Net Assets	Profit & Loss	Net Assets	Profit & Loss	Net Assets	Profit & Loss
Opening Balance	246.02	238.17	216.34	-	15.01	-
Minority Interest in Share Capital	-	-	-	-	215.63	-
Add: Minority Interest in Opening Reserve & Surplus (Credit Balance)	-	-	-	-	(15.94)	-
Less: Minority Interest in opening Reserve & Surplus (Debit Balance)	127.17	7.85	22.00	1.64	-	-
Add: Minority Interest in current period Profit	(0.10)	-	(0.17)	-	-	-
Less: Minority Interest in current period loss	-	-	-	-	-	-
<b>Total...</b>	<b>373.09</b>	<b>246.02</b>	<b>238.17</b>	<b>216.34</b>		

a. Disclosure of Subsidiaries' Share in Consolidated Net Assets and Profit and Loss

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022	
	Net Assets	Profit & Loss	Net Assets	Profit & Loss	Net Assets	Profit & Loss
Parent Company Chandan Healthcare Limited	5,430.99	1,614.92	4,109.07	1,627.63	2,393.06	(110.90)
<b>Total Consolidated Net Assets &amp; Net Profit</b>	<b>5,430.99</b>	<b>1,614.92</b>	<b>4,109.07</b>	<b>1,627.63</b>	<b>2,393.06</b>	<b>(110.90)</b>
<b>Parent Indian Subsidiaries</b>						
Chandan Diagnostic Limited	49.11	(0.33)	47.42	1.67	48.56	1.23
Chandan Pharmacy Limited	820.74	306.76	530.17	15.79	482.01	2.89
Indira Diagnostic Centre & Blood Bank Limited	351.02	(0.22)	(140.48)	16.40	(64.50)	20.30
<b>Total Subsidiaries Net Assets &amp; Net Profit</b>	<b>1,220.86</b>	<b>306.21</b>	<b>437.11</b>	<b>33.86</b>	<b>466.07</b>	<b>24.22</b>
<b>Percentage of Subsidiaries share in consolidated net assets and profit</b>						
Chandan Diagnostic Limited (% Holding 67.99%)	0.90%	-0.02%	1.15%	0.10%	2.03%	-1.11%
Chandan Pharmacy Limited (% Holding 53.56%)	15.11%	19.00%	12.90%	0.97%	20.14%	-2.43%
Indira Diagnostic Centre & Blood Bank Limited (% Holding 100%)	6.46%	-0.01%	-3.42%	1.01%	-2.70%	-18.30%
<b>Total percentage</b>	<b>22.45%</b>	<b>18.96%</b>	<b>10.64%</b>	<b>2.08%</b>	<b>19.48%</b>	<b>-21.84%</b>

b. Disclosure of minority interest in all subsidiaries

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022	
	Share Capital	Reserve & Surplus	Share Capital	Reserve & Surplus	Share Capital	Reserve & Surplus
Parent Indian Subsidiaries	31.01	(16.21)	14.80	(15.18)	31.01	(15.71)
Chandan Diagnostic Limited	15.00	374.29	389.29	253.18	15.00	245.84
Chandan Pharmacy Limited	-	-	-	-	-	-
Indira Diagnostic Centre & Blood Bank Limited	46.01	358.08	404.09	238.00	46.01	208.31
<b>Total...</b>	<b>92.02</b>	<b>396.16</b>	<b>1,008.18</b>	<b>536.16</b>	<b>92.02</b>	<b>254.31</b>



Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Surplus/Retained earning				
Opening balance Reserves & Surplus	2,116.07	736.87	400.07	839.08
Less :- Dividend on equity shares	(300.00)	(248.45)	-	(15.00)
Add: Minority Interest in Opening Reserve & Surplus(Credit Balance)	-	-	-	(215.63)
Less: Minority Interest in opening Reserve & Surplus(Debit Balance)	-	-	-	15.94
Add: Parent Interest in pre-acquisition profit	-	-	-	-
Less: Parent Interest in pre-acquisition loss	-	-	-	(13.42)
Add :- Issue of bonus share	-	-	-	-
Less :- Transfer from	-	-	-	-
Add :- Transfer to	-	-	-	-
Less :- Profit/(Loss) for the period	1,614.92	1,627.65	336.80	(110.90)
Closing balance	3,430.99	2,116.07	736.87	400.07



Notes to financial statements for the nine months ended 31st December, 2024

Note No. : 6 : Long-term borrowings

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022	
	Non current	Current	Non current	Current	Non current	Current	Non current	Current
Secured								
Bonds								
Debentures								
Term loans	1,974.05	1,217.56	789.04	434.58	234.61			
- From banks								
- From other parties								
Deferred payment liabilities								
- Deferred GST/income tax liabilities								
- Deferred payments for the acquisition of tangible and intangible assets								
Deposits								
- Deposits accepted from the public								
- Inter company deposits								
- Other deposits in the nature of borrowings								
Loans and advances from related parties								
Finance lease obligation due beyond 12 months								
Other loans and advances								
Unsecured								
Bonds								
Debentures								
Term loans								
- From banks								
- From other parties								
Deferred payment liabilities								
- Deferred GST/income tax liabilities								
- Deferred payments for the acquisition of tangible and intangible assets								
Deposits								
- Deposits accepted from the public								
- Inter company deposits								
- Other deposits in the nature of borrowings								
Loans and advances from related parties								
Finance lease obligation due beyond 12 months								
Other loans and advances								
<b>Total...</b>	<b>1,974.05</b>	<b>1,217.56</b>	<b>789.04</b>	<b>670.08</b>	<b>0.89</b>			

a. Reconciliation of current and non current portion of long term liabilities

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022	
	Non current	Current	Non current	Current	Non current	Current	Non current	Current
Secured								
Term loans	1,974.05	767.17	2,741.22	585.60	1,803.16	789.04	434.58	234.13
- From banks LTBS								
- From other parties LTBS								
Unsecured								
Term loans								
- From banks LTBUS								
- From other parties LTBUS								
<b>Total...</b>	<b>1,974.05</b>	<b>767.17</b>	<b>2,741.22</b>	<b>585.60</b>	<b>1,803.16</b>	<b>789.04</b>	<b>670.08</b>	<b>361.01</b>



Notes to restated consolidated financial statements.

b. Other disclosures on term loan

Particulars	Restated Consolidated figures as at the end of 31st December, 2024		Restated Consolidated figures as at the end of 31st March, 2024		Restated Consolidated figures as at the end of 31st March, 2023		Restated Consolidated figures as at the end of 31st March, 2022		Details of repayment terms and maturity*		Nature of Security
	Amount	ROI	Amount	ROI	Amount	ROI	Amount	ROI	Particulars	Terms	
Secured Term Loan from Bank State Bank of India [41626319793]	-	-	35.42	7.95%	69.62	7.95%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 83.00 2.56 30.00 05/06/2025	The loan is secured by the following: 1. <b>Primary Security</b> :- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. <b>Collateral Security</b> : A pari passu charge on immovable property, shared equally with other lenders who have similar security interests in the same property. This provides additional security for the lender, aligning their claim with those of other creditors. 3. <b>Personal Guarantee</b> : A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity. 4. <b>Corporate Guarantee</b> : A guarantee provided by AmarAnita Holdings (India) Pvt Ltd, ensuring that it will fulfill the loan obligations if the primary borrower fails to do so.
State Bank of India [41626315993]	-	-	208.67	7.95%	279.12	7.95%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 308.00 7.21 50.00 17/10/2024	
State Bank of India [41626340656]	-	-	16.63	7.95%	33.39	7.95%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 40.00 1.62 27.00 17/10/2024	
State Bank of India [41623614536]	-	-	42.48	8.30%	45.67	7.95%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	28/02/2023 46.00 1.19 49.00 17/10/2024	
Indusind Bank [732000008552]	71.68	8.30%	160.45	8.75%	270.51	8.30%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	01/07/2022 340.24 10.74 36.00 07/08/2025	
Yes Bank Limited [MEN00180126]	55.11	8.75%	68.90	9.00%	85.93	8.75%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	21/07/2022 96.66 2.00 60.00 22/07/2027	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
Yes Bank Limited [MEN001801285372]	11.86	8.75%	14.74	7.95%	18.26	9.00%	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	09/08/2022 20.20 0.42 60.00 22/08/2027	
HDFC Loan A/c No. [800450335]	162.73	9.50%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 178.13 6.50 31 07/04/2027	
HDFC Loan A/c No. [800450336]	6.05	9.50%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 9.57 1.24 8 07/05/2025	The loan is secured by the following: 1. <b>Primary Security</b> :- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. <b>Personal Guarantee</b> : A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity.
HDFC Loan A/c No. [800487587]	32.77	9.50%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 35.99 1.35 30.00 07/05/2027	
HDFC Loan A/c No. [99903818]	15.88	9.50%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	22/08/2024 22.43 2.34 10 07/07/2025	





PNB LOAN A/c No. [241400C/000000057]	1,199.52	8.80%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	27/07/2024 1,650.00 19.84 84 30/04/2032	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
PNB LOAN A/c No. [241400NG00259633]	16.54	8.80%	-	-	-	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	04/10/2024 17.00 0.35 60.00 30/09/2030	Hypothecation of New Four Wheeler vehicle.
Punjab National Bank [241400C/000000028]	1,169.08	7.95%	1,255.88	236.30	7.95%	-	-	-	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	31/03/2023 1,530.00 39.36 48.00 31/03/2028	The loan is secured by: 1. A first pari passu charge on the assets acquired with the proceeds of the loan. 2. The personal guarantee of all directors of the borrowing entity. 3. The corporate guarantee of AmarAnita
Indian Overseas Bank [068403510000002]	-	-	-	-	-	-	114.18	7.85%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	04/07/2020 14,800,000.00 462,755.00 36.00 01/02/2023	
Indian Overseas Bank [068403620000018]	-	-	-	-	-	-	46.85	9.15%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	02/02/2022 4,685,000.00 29,220.00 36.00 01/02/2023	
Indian Overseas Bank [068403602000002]	-	-	-	-	-	-	349.27	9.15%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	13/10/2021 35,000,000.00 245,160.00 59.00 01/02/2023	The loan is secured by the following: 1. Primary Security- A first pari passu charge on the assets acquired with the proceeds of the loan. This gives the lender a primary claim on these assets, ensuring that their security interest is prioritized above other claims. 2. Collateral Security: A pari passu charge on immovable property, shared equally with other lenders who have similar security interests in the same property. This provides additional security for the lender, aligning their claim with those of other creditors. 3. Personal Guarantee: A guarantee provided by all directors of the borrowing entity, holding them personally liable for the loan obligations in the event of default by the borrowing entity. 4. Corporate Guarantee: A guarantee provided by AmarAnita Holdings (India) Pvt Ltd, ensuring that it will fulfill the loan obligations if the primary borrower fails to do so.
Indian Overseas Bank [068403602000003]	-	-	-	-	-	-	50.00	9.15%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	13/10/2021 5,000,000.00 35,096.00 35.00 01/02/2023	
Indian Overseas Bank [068403707000002]	-	-	-	-	-	-	108.42	9.15%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	06/04/2017 79,400,000.00 1,626,714.82 60.00 01/02/2023	
Term loans from other parties Moneywise Financial Services P Ltd [ME00023]	-	-	-	-	-	-	84.87	14.00%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	13/08/2020 10,144,665.00 335,000.00 48.00 01/08/2022	
Moneywise Financial Services P Ltd [ME00013]	-	-	-	-	-	-	221.99	12.50%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	13/09/2018 42,100,000.00 959,076.00 63.00 01/08/2022	The loan is secured by a first pari passu charge on the assets acquired using the proceeds of this loan, establishing a primary security interest.
Moneywise Financial Services Pvt Ltd [CHL01]	-	-	-	-	-	-	54.13	12.50%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	30/06/2017 27,000,000.00 614,333.00 60.00 29/07/2022	
Unsecured Term loans from other parties Capital Float Financial Services Private Ltd	-	-	-	-	-	-	1.38	15.00%	Sanction date Principal amount EMI amount Loan period (Month)# Last Instalment date	-	
Total....	2,741.22		1,803.16	1,038.79			1,031.09				

\* These are with respect to the balance sheet date.  
# The figures are presented in absolute terms and are not expressed in lakhs.

0.00

Check

Notes to financial statements for the nine months ended 31st December, 2024

**Note No. :- 9 : Long term provisions**

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Provision for gratuity Others(specifying the nature)	326.54 -	305.75 -	218.41 -	215.92 -
<b>Total...</b>	<b>326.54</b>	<b>305.75</b>	<b>218.41</b>	<b>215.92</b>

a. Details of employee benefits as required by the accounting standard 15 (revised) employee benefits are as under:  
The company has classified the various benefits provided to employee's as under:-

**I. Defined contribution plans**

- a. Employee's provident fund.  
b. Employee's state insurance.

During the year, the company has recognised the following amounts in the profit and loss account:

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Employers' contribution to provident fund*	71.10	75.92	36.23	33.96
Employers' contribution to employee's state insurance*	23.61	30.91	14.50	13.99
<b>Total...</b>	<b>94.71</b>	<b>106.83</b>	<b>50.73</b>	<b>47.95</b>

\* Included in Contribution to Provident and Other Funds (Refer Note No. 28 Employee benefits expense)

**II. Defined benefit plans**

Gratuity disclosures as per accounting standard-15

(i) Table Showing Changes in Present Value of Obligations

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Present value of the obligation at the beginning of the period	340.43	235.93	250.74	190.15
Interest cost	18.51	17.69	18.18	13.79
Current service cost	50.49	52.37	31.80	32.97
Past Service Cost	-	-	-	-
Benefits paid (if any)	(9.68)	(7.96)	(117.68)	(24.77)
Actuarial (gain)/loss	(6.18)	19.71	52.89	38.60
<b>Present value of the obligation at the end of the period</b>	<b>393.58</b>	<b>317.73</b>	<b>235.93</b>	<b>250.74</b>

(ii) Key results (The amount to be recognized in the Balance Sheet):

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Present value of the obligation at the end of the period	393.58	317.73	235.93	250.74
Fair value of plan assets at end of period	-	-	-	-
Net liability/(asset) recognized in Balance Sheet and related analysis	393.58	317.73	235.93	250.74
Funded Status - Surplus/ (Deficit)	(393.58)	(317.73)	(235.93)	(250.74)

(iii) Expense recognized in the statement of Profit and Loss:

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Interest cost	18.51	17.69	18.18	13.79
Current service cost	50.49	52.37	31.80	32.97
Past Service Cost	-	-	-	-
Expected return on plan asset	-	-	-	-
Net actuarial (gain)/loss recognized in the period	(6.18)	19.71	52.89	38.60
<b>Expenses to be recognized in P&amp;L #</b>	<b>62.82</b>	<b>89.77</b>	<b>102.87</b>	<b>85.36</b>

# Included in Provision for gratuity (Refer Note No. 28 Employee benefits expense)

(iv) Current & Non Current Liability :

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Current Liability (Short Term)^	67.04	34.68	30.37	34.82
Non Current Liability (Long Term)	326.54	305.75	218.41	215.92
<b>Total Liability</b>	<b>393.58</b>	<b>340.43</b>	<b>248.78</b>	<b>250.74</b>

^ Included in Provision for gratuity (Refer Note No. 12 Short term provisions)





(v) Reconciliation of liability in balance sheet

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Opening gross defined benefit liability/ (asset)	340.43	235.93	250.74	190.15
Expenses to be recognized in P&L	62.82	89.77	102.87	85.36
Benefits paid (if any)	(9.68)	(7.96)	(117.68)	(24.77)
<b>Closing gross defined benefit liability/ (asset)</b>	<b>393.58</b>	<b>317.73</b>	<b>235.93</b>	<b>250.74</b>

(vi) Actuarial assumptions provided by the company and employed for the calculations are tabulated:

Particulars	Consolidated figures as at the end of 31st December, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
Discount rate	7.00 % p.a.	7.25 % p.a.	7.50 % p.a.	7.50 % p.a.
Salary Growth Rate	8.00 % p.a.	8.00 % p.a.	8.00 % p.a.	8.00 % p.a.
Mortality	IALM 2012-14	IALM 2012-14	IALM 2012-14	IALM 2012-14
Expected rate of return	-	-	-	-
Attrition / Withdrawal Rate (per Annum)	10.00% p.a.	5.00% p.a.	5.00% p.a.	5.00% p.a.



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 7 : Deferred tax liabilities(Net)

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Deferred tax liabilities(Net)	198.25	139.36	139.43	108.25
<b>Total...</b>	<b>198.25</b>	<b>139.36</b>	<b>139.43</b>	<b>108.25</b>

a. Disclosures regarding the components of net deferred tax liabilities

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Provision for gratuity	(99.06)	(79.97)	(25.89)	-
Provision for doubtful debts	(5.22)	(1.32)	-	-
Provision for obsolete inventories	(7.74)	(1.58)	-	-
W.D.V of property, plant & equipments & intangible assets	310.27	222.22	165.32	108.25
<b>Total...</b>	<b>198.25</b>	<b>139.36</b>	<b>139.43</b>	<b>108.25</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 8 : Other long -term liabilities

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Trade payables</b>				
- Total outstanding dues of micro enterprises and small enterprises	-	-	-	-
- Total outstanding dues of other then micro enterprises and small enterprises	-	-	-	-
<b>Other long-term liabilities</b>				
- Trade deposits and security deposits which are not in the nature of borrowings	0.45	0.45	0.65	0.65
- Others(Specifying the nature)	-	-	-	-
<b>Total...</b>	<b>0.45</b>	<b>0.45</b>	<b>0.65</b>	<b>0.65</b>





Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 11 : Trade payables

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Trade payables</b>				
- Total outstanding dues of micro enterprises and small enterprises	531.57	626.71	337.45	144.13
- Total outstanding dues of other than micro enterprises and small enterpr	3,817.66	1,517.35	3,156.74	2,515.54
<b>Total...</b>	<b>4,349.23</b>	<b>2,144.06</b>	<b>3,494.19</b>	<b>2,659.67</b>

a. Trade payables ageing schedule  
As at 31st Dec, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Not Disputed</b>							
--MSME	-	531.57	-	-	-	-	531.57
--Others	-	-	3,817.66	-	-	-	3,817.66
<b>Disputed</b>							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
<b>Total...</b>	<b>-</b>	<b>531.57</b>	<b>3,817.66</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4,349.23</b>

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Not Disputed</b>							
--MSME	-	626.71	-	-	-	-	626.71
--Others	-	-	1,517.35	-	-	-	1,517.35
<b>Disputed</b>							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
<b>Total...</b>	<b>-</b>	<b>626.71</b>	<b>1,517.35</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,144.06</b>

As at 31st March, 2023

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Not Disputed</b>							
--MSME	-	337.45	-	-	-	-	337.45
--Others	-	-	3,156.74	-	-	-	3,156.74
<b>Disputed</b>							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
<b>Total...</b>	<b>-</b>	<b>337.45</b>	<b>3,156.74</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>3,494.19</b>

As at 31st March, 2022

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of payment				TOTAL
			Less than 1 year	1-2 years	2-3 years	More than 3 years	
<b>Not Disputed</b>							
--MSME	-	144.14	-	-	-	-	144.14
--Others	-	-	2,515.54	-	-	-	2,515.54
<b>Disputed</b>							
--MSME	-	-	-	-	-	-	-
--Others	-	-	-	-	-	-	-
<b>Total...</b>	<b>-</b>	<b>144.14</b>	<b>2,515.54</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,659.68</b>

b. Disclosure as per MSMED Act, 2006

Particulars	consolidated figures as at the end of 31st Dec, 2024	consolidated figures as at the end of 31st March, 2024	consolidated figures as at the end of 31st March, 2023	consolidated figures as at the end of 31st March, 2022
<b>Payable</b>				
Principle overdue as per MSMED Act,2006.	-	-	-	-
Principle not due as per MSMED Act,2006.	531.57	626.71	337.45	144.14
Interest payable under section 16 of MSMED Act, 2006	-	-	-	-
- On principle paid beyond due date as per MSMED Act,2006	-	-	-	-
- On principle payable beyond due date as per MSMED Act,2006	-	-	-	-
- Carried forward from the last year	-	-	-	-
Other interest	-	-	-	-
<b>Total...</b>	<b>531.57</b>	<b>626.71</b>	<b>337.45</b>	<b>144.14</b>
<b>Paid</b>				
Principle paid beyond the due date as per MSMED Act,2006	-	-	-	-
Interest paid under section 16 of MSMED Act, 2006	-	-	-	-
<b>Total...</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 12 : Other current liabilities

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Current maturities of finance lease obligations	-	-	-	-
Interest accrued but not due on borrowings	-	-	-	-
Interest accrued and due on borrowings	-	-	-	-
Income received in advance	-	-	-	-
Unpaid dividends	-	-	-	-
Application money received for allotment of securities and due for refund and interest accrued thereon	-	-	-	-
Trade deposits and security deposits which are not in the nature of borrowings	-	-	-	-
Advances from customers	10.31	1,070.22	344.62	542.68
TDS payable	30.09	59.77	43.20	58.95
GST payable	64.18	10.97	3.21	6.03
Salary, Bonus, Gratuity, Reimbursements etc. payable to staff	633.17	387.19	370.47	192.18
Contribution towards PF payable	15.95	15.04	5.18	14.03
Contribution towards ESI payable	3.44	2.99	1.34	5.34
Income tax payable OCL	123.06	12.73	-	-
Other payables (specify nature)	-	-	-	-
<b>Total...</b>	<b>880.20</b>	<b>1,558.91</b>	<b>768.02</b>	<b>819.21</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 13 : Short term provisions

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Provision for employee benefits				
Provision for gratuity	67.04	34.68	30.37	34.82
Others	-	-	-	-
Provision for dividend	-	-	-	-
Provision for taxation	188.15	139.81	20.89	9.65
Provision for warranties	-	-	-	-
Other provision(specify nature)	-	-	-	-
	255.19	174.49	51.26	44.47



Notes to consolidated financial statements.

Note No. :- 14 : Property, plant & equipments & Intangible assets  
Consolidated as at 31st Dec, 2024

Description	Gross block			consolidated figures as at the end of 31st Dec, 2024	Accumulated depreciation			Net block	
	Figures as at the beginning of 1st April, 2024	Additions during the year	Disposals during the year		Figures as at the beginning of 1st April, 2024	For the year	consolidated figures as at the end of 31st Dec, 2024	consolidated figures as at the end of 31st Dec, 2024	consolidated figures as at the end of 31st March, 2024
<b>Tangible Assets</b>									
<b>Property, plant and equipment</b>									
Computers	484.46	12.84	-	497.30	335.41	48.78	384.18	113.11	149.05
Electric Installation	110.49	16.71	-	127.20	80.14	2.95	83.08	44.12	30.35
Office Interior & Renovation	529.18	313.16	-	842.34	312.02	27.14	339.15	503.19	217.16
Buildings	322.51	-	-	322.51	85.54	3.83	89.37	233.14	236.97
Plant and equipment	5,964.24	1,964.42	-	7,928.65	2,459.05	289.11	2,748.15	5,180.50	3,505.19
Furniture and fixtures	159.17	32.29	-	191.45	109.10	6.68	115.78	75.67	50.07
Vehicles	104.71	29.42	-	134.14	79.35	3.65	83.00	51.14	25.37
Office equipment	309.40	90.48	-	399.88	117.45	22.80	140.24	260.24	191.95
<b>Total...</b>	<b>7,984.15</b>	<b>2,459.32</b>	<b>-</b>	<b>10,443.47</b>	<b>3,578.04</b>	<b>404.92</b>	<b>3,982.96</b>	<b>6,461.11</b>	<b>4,406.11</b>
<b>Intangible Assets</b>									
Goodwill	443.27	-	-	443.27	-	-	-	443.27	443.27
<b>Total...</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>443.27</b>

Consolidated as at 31st March, 2024

Description	Gross block				Figures as at the beginning of 1st April, 2023	For the year	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2024	Restated consolidated figures as at the end of 31st March, 2023
	Figures as at the beginning of 1st April, 2023	Additions during the year	Disposals during the year	Restated consolidated figures as at the end of 31st March, 2024					
<b>Tangible Assets</b>									
<b>Property, plant and equipment</b>									
Computers	368.92	115.54	-	484.46	295.70	39.71	335.41	149.05	73.22
Electric Installation	94.78	15.71	-	110.49	77.38	2.76	80.14	30.35	17.40
Office Interior & Renovation	398.12	131.06	-	529.18	293.24	18.78	312.02	217.16	104.88
Buildings	310.13	12.38	-	322.51	80.61	4.93	85.54	236.97	229.52
Plant and equipment	4,393.07	1,571.17	-	5,964.24	2,211.73	247.32	2,459.05	3,505.19	2,181.34
Furniture and fixtures	143.04	16.13	-	159.17	102.43	6.67	109.10	50.07	40.61
Vehicles	88.45	16.26	-	104.71	76.01	3.34	79.35	25.37	12.45
Office equipment	253.47	55.93	-	309.40	100.56	16.89	117.45	191.96	152.91
<b>Total...</b>	<b>6,049.97</b>	<b>1,934.18</b>	<b>-</b>	<b>7,984.15</b>	<b>3,237.64</b>	<b>340.40</b>	<b>3,578.04</b>	<b>4,406.12</b>	<b>2,812.33</b>
<b>Intangible Assets</b>									
Goodwill	443.27	-	-	443.27	-	-	-	443.27	443.27
<b>Total...</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>443.27</b>





Consolidated as at 31st March, 2023

Description	Gross block				Accumulated depreciation			Net block	
	Figures as at the beginning of 2022	Additions during the year	Disposals during the year	Figures as at the end of 31st March, 2023	Figures as at the beginning of 2022	For the year	Figures as at the end of 31st March, 2023	Figures as at the end of 31st March, 2023	Figures as at the end of 31st March, 2022
<b>Tangible Assets</b>									
<b>Property, plant and equipment</b>									
Computers	340.34	28.58	-	368.92	271.49	24.20	295.70	73.22	68.85
Electric Installation	90.53	4.25	-	94.78	75.77	1.61	77.38	17.40	14.76
Office Interior & Renovation	366.45	31.66	-	398.12	290.43	2.80	293.24	104.88	76.02
Buildings	310.13	-	-	310.13	76.73	3.87	80.61	229.52	233.39
Plant and equipment	3,990.30	402.76	-	4,393.07	2,050.99	160.74	2,211.73	2,181.34	1,939.31
Furniture and fixtures	121.18	21.86	-	143.04	98.96	3.47	102.43	40.61	22.22
Vehicles	80.03	8.42	-	88.45	74.83	1.18	76.01	12.46	5.20
Office equipment	223.07	30.40	-	253.47	89.48	11.08	100.56	152.91	133.58
<b>Total...</b>	<b>5,522.03</b>	<b>527.94</b>	<b>-</b>	<b>6,049.97</b>	<b>3,028.69</b>	<b>208.95</b>	<b>3,237.64</b>	<b>2,812.34</b>	<b>2,493.34</b>
<b>Intangible Assets</b>									
Goodwill	443.27	-	-	443.27	-	-	-	443.27	443.27
<b>Total...</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>443.27</b>

Consolidated as at 31st March, 2022

Description	Gross block				Accumulated depreciation			Net block	
	Figures as at the beginning of 2021	Additions during the year	Disposals during the year	Figures as at the end of 31st March, 2022	Figures as at the beginning of 2021	For the year	Figures as at the end of 31st March, 2022	Figures as at the end of 31st March, 2022	Figures as at the end of 31st March, 2021
<b>Tangible Assets</b>									
<b>Property, plant and equipment</b>									
Computers	280.41	59.93	-	340.34	259.12	12.37	271.49	68.85	21.28
Electric Installation	81.48	9.05	-	90.53	73.69	2.07	75.77	14.76	7.79
Office Interior & Renovation	300.27	66.19	-	366.45	283.10	7.33	290.43	76.02	17.17
Buildings	310.13	-	-	310.13	72.80	3.94	76.73	233.39	237.33
Plant and equipment	3,491.22	499.09	-	3,990.30	1,897.95	153.04	2,050.99	1,939.31	1,593.27
Furniture and fixtures	112.88	8.29	-	121.18	96.59	2.37	98.96	22.22	16.30
Vehicles	73.20	6.83	-	80.03	72.70	2.13	74.83	5.21	0.50
Office equipment	208.25	14.81	-	223.07	76.68	12.81	89.48	133.58	131.58
<b>Total...</b>	<b>4,857.84</b>	<b>664.19</b>	<b>-</b>	<b>5,522.03</b>	<b>2,832.63</b>	<b>196.06</b>	<b>3,028.69</b>	<b>2,493.35</b>	<b>2,025.21</b>
<b>Intangible Assets</b>									
Goodwill	-	443.27	-	443.27	-	-	-	443.27	-
<b>Total...</b>	<b>-</b>	<b>443.27</b>	<b>-</b>	<b>443.27</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>443.27</b>	<b>-</b>



Notes to financial statements for the nine months

Note No. :- 15 : Non-current investments

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Investment property	-	-	-	-
Investments in equity instruments	337.72	337.72	422.52	579.91
Investments in preference shares	-	-	-	-
Investments in government or trust securities	-	-	-	-
Investments in debentures or bonds redeemable after 12 m	-	-	-	-
Investments in mutual funds	-	-	-	-
Investments in partnership firms	-	-	-	-
Application money paid towards securities	-	-	-	-
Investment in LLP	-	-	-	-
Other non-current investments(specify nature)	-	-	-	-
Less: Provision for other than temporary diminution in the value of non current investments	-	-	-	-
Less: Adjustments to the carrying amount of investments on account of revaluation etc	-	-	-	-
Add: Adjustments to the carrying amount of investments on account of revaluation etc	-	-	-	-
<b>Total...</b>	<b>337.72</b>	<b>337.72</b>	<b>422.52</b>	<b>579.91</b>

a. Disclosure on investment in equity instrument  
As at 31st Dec, 2024

Name of body corporate	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	10	Fully paid	17.58%	1.25	270	337.72	Cost	Unquoted
<b>Total...</b>						<b>337.72</b>		

As at 31st March, 2024

Name of body corporate	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	10	Fully paid	17.58%	1.25	270	337.72	Cost	Unquoted
<b>Total...</b>						<b>337.72</b>		

As at 31st March, 2023

Name of body corporate	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Institute of Medical Science Limited	10	Fully paid	17.58%	123.01	2.75	337.74	Cost	Unquoted
Chandan Hospital Limited	10	Fully paid	1.60%	8.48	10.00	84.79	Cost	Unquoted
<b>Total...</b>						<b>422.52</b>		

As at 31st March, 2022

Name of body corporate	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/ Unquoted Investment
Chandan Hospital Limited	2.5	Partly paid	1.46%	37.10	6.53	242.20	Cost	Unquoted
Chandan Institute of Medical Sciences Limited	10	Partly paid	17.58%	123.01	2.75	337.72	Cost	Unquoted
<b>Total...</b>						<b>579.91</b>		



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 16 : Long -term loans and advances

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Secured, considered good</b>				
Capital Advances	525.59	44.06	316.37	38.74
Loans and advances to related parties	-	-	-	-
Advance to supplier	-	-	-	-
Advance to employees	-	-	-	-
Other loans and advances (specify nature)	-	-	-	-
<b>Unsecured, considered good</b>				
Capital Advances	-	-	-	-
Loans and advances to related parties	-	-	-	-
Advance to supplier	-	-	-	-
Advance to employees	-	-	-	-
Income tax refund due	77.72	77.54	77.54	93.25
Other loans and advances (specify nature)	-	-	-	-
<b>Doubtful</b>				
Capital Advances	-	-	-	-
Loans and advances to related parties	-	-	-	-
Advance to supplier	-	-	-	-
Advance to employees	-	-	-	-
Other loans and advances (specify nature)	-	-	-	-
Less: Provision for bad and doubtful loans and advances	-	-	-	-
<b>Total...</b>	<b>603.31</b>	<b>121.60</b>	<b>393.91</b>	<b>131.99</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493  
Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 17 : Other non-current assets

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Secured, considered good</b>				
Long term trade receivables (including trade receivables on deferred credit terms)	-	-	-	-
Security Deposits	162.66	97.38	59.61	54.98
Banks deposits with more than twelve months maturity	26.78	264.78	295.50	104.17
Others (specify nature)	-	-	-	-
<b>Unsecured, considered good</b>				
Long term trade receivables (including trade receivables on deferred credit terms)	-	-	-	-
Security Deposits	-	-	-	-
Others (specify nature)	-	-	-	-
<b>Doubtful</b>				
Long term trade receivables (including trade receivables on deferred credit terms)	-	-	-	-
Security Deposits	-	-	-	-
Others (specify nature)	-	-	-	-
Less: Provision for bad and doubtful other non-current assets	-	-	-	-
<b>Total...</b>	<b>189.44</b>	<b>362.16</b>	<b>355.11</b>	<b>159.15</b>



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st

Note No. :- 18 : Current investments

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Investment property	-	-	286.17	-
Investments in equity instruments	-	-	-	-
Investments in preference shares	-	-	-	-
Investments in government or trust securities	-	-	-	-
Investments in debentures or bonds redeemable within 12 month	-	-	-	-
Investments in mutual funds	-	-	-	-
Investments in partnership firms	-	-	-	-
Application money paid towards securities	-	-	-	-
Investment in LLP	-	-	-	-
Other non-current investments (specify nature)	-	-	-	-
Less: Provision for other than temporary diminution in the value of non	-	-	-	-
Less: Adjustments to the carrying amount of investments on account of	-	-	-	-
Add: Adjustments to the carrying amount of investments on account of	-	-	-	-
<b>Total...</b>	-	-	<b>286.17</b>	-

a. Disclosure on investment in equity instrument

As at 31st March, 2023

Name of body corporate	Nature of Investment	Paid up value/share	Fully or partly paid	(%) holding	No of shares	Issue price	Amount	Basis of Valuation	Quoted/Unquoted Investment
Chandan Hospital Limited,	Associates	10	Fully paid	9.66%	28.62	10	286.17	Cost	Unquoted
<b>Total...</b>							<b>286.17</b>		



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 19 : Inventories

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Raw materials	-	-	-	-
Packing materials	-	-	-	-
Work-in-progress	-	-	-	-
Finished goods	-	-	-	-
Stock-in-trade	1,626.32	1,251.59	987.12	656.03
Stores,spares and consumables	1,531.98	579.04	-	-
Loose tools	-	-	-	-
Goods- In- Transit	-	-	-	-
Purchased intermediates and components consumed In the manufacturing activities of company	-	-	-	-
Others (specify nature)	-	-	-	-
Less: Provision for stock obsolescence	(30.75)	(6.26)	-	-
<b>Total...</b>	<b>3,127.55</b>	<b>1,824.37</b>	<b>987.12</b>	<b>656.03</b>

# During the financial year 2023-2024 the company has revised its accounting policy regarding the treatment of consumables transferred to various diagnostic centers. Under the previous policy, these consumables were expensed at the time of transfer. Given the significance of the consumable stock consistently held at these centers, the company has adopted a new policy wherein consumables transferred to diagnostic centers are recognized as inventory at those centers and are expensed only when consumed or used.

As a result of this policy change, the profit before tax for the current financial year has increased by Rs 579.04 Lakhs, representing a 27.70% increase. This adjustment reflects a one-time impact on the current year's profit and is not expected to materially affect profitability in future periods.

In accordance with Accounting Standard (AS) 5, "Net Profit or Loss for the Period, Prior Period Items and Changes in Accounting Policies," prior period items include errors discovered in the preparation of financial statements for one or more prior periods. Such errors may arise from mathematical mistakes, incorrect application of accounting policies, misinterpretation of facts, or oversight. Given that the revised policy addresses an error in the application of the previous accounting policy, the resulting increase in profit of Rs 579.04 Lakhs should be classified as a prior period item.



Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 20 : Trade receivables

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
Secured, considered good Trade receivables	3,972.74	2,661.29	2,368.84	2,869.81
Unsecured, considered good Trade receivables	-	-	-	-
Doubtful Trade receivables	-	-	-	-
Less: Provision for bad and doubtful trade receivables	(20.75)	(5.24)	-	-
<b>Total...</b>	<b>3,951.99</b>	<b>2,656.05</b>	<b>2,368.84</b>	<b>2,869.81</b>

a. Trade receivable ageing schedule  
As at 31st Dec, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	473.90	3,498.84	-	-	-	-	3,972.74
Trade Receivables – considered doubtful	-	-	20.75	-	-	-	-	20.75
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
<b>Total...</b>	-	<b>473.90</b>	<b>3,519.59</b>	-	-	-	-	<b>3,951.99</b>

As at 31st March, 2024

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	555.68	2,105.61	-	-	-	-	2,661.29
Trade Receivables – considered doubtful	-	-	5.24	-	-	-	-	5.24
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
<b>Total...</b>	-	<b>555.68</b>	<b>2,110.85</b>	-	-	-	-	<b>2,656.05</b>

As at 31st March, 2023

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	346.41	2,022.43	-	-	-	-	2,368.84
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
<b>Total...</b>	-	<b>346.41</b>	<b>2,022.43</b>	-	-	-	-	<b>2,368.84</b>

As at 31st March, 2022

Particulars	Unbilled dues	Not dues	Outstanding for following periods from due date of receipt					TOTAL
			Less than 6 Month	6 Months - 1 year	1-2 years	2-3 years	More than 3 years	
UnDisputed								
Trade Receivables – considered good	-	223.35	2,646.46	-	-	-	-	2,869.81
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
Disputed								
Trade Receivables – considered good	-	-	-	-	-	-	-	-
Trade Receivables – considered doubtful	-	-	-	-	-	-	-	-
<b>Total...</b>	-	<b>223.35</b>	<b>2,646.46</b>	-	-	-	-	<b>2,869.81</b>



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 21 : Cash and bank balances

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Cash and cash equivalents</b>				
Balances with banks	70.57	355.33	71.82	46.42
Cheques, drafts on hand	-	-	-	-
Demand Deposit With Bank	-	-	-	-
Cash on hand	31.39	34.65	107.58	84.12
Short term(Less than 3 month),highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.	-	-	-	-
Bank deposits with Less than three months maturity	-	-	-	-
<b>Others</b>				
Balances with banks to the extent held as margin money or security against the borrowings, guarantees, other commitments	-	-	-	-
Repatriation restrictions, if any, in respect of cash and bank balances	-	-	-	-
Bank deposits with more than three months maturity	940.58	134.66	25.06	27.09
<b>Total...</b>	<b>1,042.54</b>	<b>524.64</b>	<b>204.46</b>	<b>157.63</b>





Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 22 : Short-term loans and advances

Particulars	Restated Consolidated figures as at the end of 31st December, 2024	Restated Consolidated figures as at the end of 31st March, 2024	Restated Consolidated figures as at the end of 31st March, 2023	Restated Consolidated figures as at the end of 31st March, 2022
<b>Secured, considered good</b>				
Loans and advances to related parties	-	1,649.66	1,137.87	513.76
Advance to supplier	315.88	280.28	219.71	19.98
Advance to employees	441.35	219.12	84.63	79.34
Other loans and advances (specify nature)	-	-	-	-
<b>Unsecured, considered good</b>				
Loans and advances to related parties	-	-	-	-
Advance to supplier	-	-	-	-
Advance to employees	-	-	-	-
Income tax refund due	24.75	0.23	48.61	8.05
Other loans and advances (specify nature)	-	-	-	-
<b>Doubtful</b>				
Loans and advances to related parties	-	-	-	-
Advance to supplier	-	-	-	-
Advance to employees	-	-	-	-
Other loans and advances (specify nature)	-	-	-	-
Less: Provision for bad and doubtful loans and advances	-	-	-	-
<b>Total...</b>	<b>781.98</b>	<b>2,149.29</b>	<b>1,490.82</b>	<b>621.13</b>

a. Other disclosures

Particulars	consolidated figures as at the end of 31st Dec, 2024		consolidated figures as at the end of 31st March, 2024		consolidated figures as at the end of 31st March, 2023		consolidated figures as at the end of 31st March, 2022	
	Amount	Nature of security and other terms	Amount	Nature of security and other terms	Amount	Nature of security and other terms	Amount	Nature of security and other terms
Loans and advances to related parties	-	-	1,649.66	Unsecured loan, repayable on demand.	1,137.87	Unsecured loan, repayable on demand.	513.76	Unsecured loan, repayable on demand.
<b>Total...</b>	<b>-</b>	<b>-</b>	<b>1,649.66</b>		<b>1,137.87</b>		<b>513.76</b>	



Chandan Healthcare Limited  
U85110UP2003PLC193493  
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 24 : Revenue from operations

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Sale of products	7,871.64	7,908.32	6,143.10	5,807.16
Sale of services	8,875.12	9,749.18	7,545.43	6,149.19
Other operating revenues	0.71	1.51	0.41	-
Sale of scrap	-	-	-	-
Less: Excise duty	-	-	-	-
<b>Total...</b>	<b>16,747.47</b>	<b>17,659.01</b>	<b>13,688.94</b>	<b>11,956.35</b>



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 25 : Other income

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
<u>On current investments</u>				
Interest on fixed deposits	42.41	24.50	7.75	5.86
Dividends from subsidiary companies	-	-	-	-
Dividends from other companies	-	75.98	-	7.16
Net gain/(loss) on sale of investments	-	-	-	-
<u>On non current investments</u>				
Interest on fixed deposits	-	-	-	-
Dividends from subsidiary companies	-	-	-	-
Dividends from other companies	-	-	-	-
Net gain/(loss) on sale of investments	-	-	-	-
<u>Other</u>				
Interest from customers on amounts overdue	-	-	-	-
Other Interest Income	-	5.93	0.29	1.53
Net gain/(loss) on sale of property, plant & equipments & intangible assets	-	-	-	-
Gain on account of foreign exchange fluctuations	-	-	-	-
Share of profits/(losses) in a partnership firm/LLP	-	-	-	-
Other non-operating income	8.94	30.44	5.94	20.68
<b>Total...</b>	<b>51.35</b>	<b>136.85</b>	<b>13.98</b>	<b>35.23</b>



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 26 : Cost of material consumed

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Raw materials	-	-	-	-
Stores,spares and consumables	980.88	1,112.68	1,388.00	967.89
Packing materials	-	-	-	-
Purchased intermediates and components consumed In the manufacturing activities of company	-	-	-	-
<b>Total...</b>	<b>980.88</b>	<b>1,112.68</b>	<b>1,388.00</b>	<b>967.89</b>

Consumption disclosed in Note is on the basis of derived figures rather than actual records of issue.



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 27 : Purchase of stock-in-trade

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Purchase of stores, spares and consumables	7,114.09	7,236.76	5,493.56	5,332.58
<b>Total...</b>	<b>7,114.09</b>	<b>7,236.76</b>	<b>5,493.56</b>	<b>5,332.58</b>



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 28 : Change in inventories of finished goods, work-in-progress and stock-in-trade.

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
<b>Opening stock:</b>				
Finished goods	-	-	-	-
Work-in-progress	-	-	-	-
Stock-in-trade	1,251.59	987.12	576.96	502.68
	<b>1,251.59</b>	<b>987.12</b>	<b>576.96</b>	<b>502.68</b>
<b>Closing stock:</b>				
Finished goods	-	-	-	-
Work-in-progress	-	-	-	-
Stock-in-trade	1,626.32	1,251.59	987.12	576.96
	<b>1,626.32</b>	<b>1,251.59</b>	<b>987.12</b>	<b>576.96</b>
<b>Total...</b>	<b>(374.73)</b>	<b>(264.47)</b>	<b>(410.16)</b>	<b>(74.28)</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493  
Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 29 : Employee benefits expense.

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Salaries and wages	2,752.88	3,331.05	2,186.59	1,724.09
Contribution to provident and other funds	94.71	106.83	50.73	47.95
Provision for gratuity	62.82	89.77	102.87	85.36
Expense on employee stock option scheme (ESOP) and employee stock purchase plan (ESPP)	-	-	-	-
Staff welfare expense	3.80	10.31	208.90	15.58
<b>Total...</b>	<b>2,914.21</b>	<b>3,537.96</b>	<b>2,549.09</b>	<b>1,872.98</b>



Chandan Healthcare Limited  
 U85110UP2003PLC193493  
 Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 30 : Finance costs

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Interest expense on borrowings	291.69	248.07	180.19	159.87
<b>Other borrowing costs</b>				
Loan processing charges	23.37	12.65	51.13	1.07
Bank charges	12.93	14.47	10.59	9.68
Dividend on redeemable preference shares	-	-	-	-
Applicable net gain/loss on foreign currency transactions and translation	-	-	-	-
	<b>327.99</b>	<b>275.19</b>	<b>241.91</b>	<b>170.62</b>





Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 31 : Other expenses

Particulars	Restated Consolidated figures for the nine months ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Repair & maintenance- Plant & equipments	80.81	75.60	73.60
Repair & maintenance-Building	22.39	33.62	21.29
Repair & maintenance- Other	89.85	58.42	20.00
Baddebts & Writtenoff	17.20	14.66	520.79
Payment to auditors	9.73	10.66	1.22
Rent	430.90	447.75	303.57
Electricity expenses	170.89	174.90	107.56
Fuel expenses	36.52	41.18	41.81
Travelling and conveyance	929.62	771.05	1,015.77
Legal and professional fees (professional fees to doctor consultants and others) & other related expenditures	897.84	1,034.99	947.78
Books, periodicals & certifications	0.73	0.61	2.11
Commission expenses	-	0.17	270.96
Advertisement, publicity, marketing & business promotion expenses	59.19	114.23	22.13
Provision for doubtful debts	15.50	5.24	-
Provision for obsolete inventories	24.49	6.26	-
Communication expenses(Telephone & internet expenses)	30.80	37.83	21.97
Insurance	5.71	6.70	3.55
Postage & courier charges	2.69	3.35	10.05
Rates and taxes	1.91	0.54	82.21
Outsourced testing expenses	55.98	364.56	79.54
CSR Expenses	12.46	6.06	-
Discount to customers	3.78	2.43	-
Other miscellaneous expenses	191.98	200.53	85.85
	<b>3,090.97</b>	<b>3,411.34</b>	<b>3,631.76</b>

a. Payment to the auditor

Particulars	Restated Consolidated figures for the nine months ended 31st December	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
For statutory audit	7.00	7.73	0.93	0.94
For tax audit	-	1.50	0.20	0.28
Out of Pocket Audit Expenses	-	1.14	-	-
Stock Audit Fees	-	0.30	-	-
<b>Total...</b>	<b>7.00</b>	<b>10.66</b>	<b>1.13</b>	<b>1.22</b>

b. Prior period items

Particulars	Restated Consolidated figures for the nine months ended 31st December,	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Rent	3.30	11.66	-	-
Electricity expenses	2.47	11.00	-	-
Communication expenses(Telephone & internet expenses)	2.74	0.36	-	-
Rates and taxes	-	1.87	-	-
Other miscellaneous expenses	12.37	0.48	-	-
<b>Total...</b>	<b>20.89</b>	<b>25.37</b>	<b>-</b>	<b>-</b>

c. Disclosure of expenditure in foreign currency during the financial year.

Particulars	Restated Consolidated figures for the nine months ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Royalty	-	-	-
Legal, professional and consultancy charges	-	-	-
Interest	-	0.44	-
Other matters(Specify nature)	-	-	-
<b>Total...</b>	<b>-</b>	<b>0.44</b>	<b>-</b>



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

**Note No. :- 32 : Earning per share**

Basic/Diluted earnings per share are calculated by dividing the Net profit or Loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period.

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
<b>Numerator</b> Earning available to equity share holders(EAESH)	1,614.92	1,627.65	336.80	(110.90)
<b>Denominator</b> Weighted average outstanding equity share capital	200.00	200.00	200.00	200.00
<b>Earnings Per Rupees of Equity Share Capital (Basic/ Diluted)</b>	<b>8.07</b>	<b>8.14</b>	<b>1.68</b>	<b>(0.55)</b>



Chandan Healthcare Limited  
 U86110UP2003PLC193483  
 Registered address - Biotech Park, Sector G, Kurali road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
 (All amounts are in ₹ lakhs, unless otherwise stated)

Notes to restated consolidated financial statements.

Note No. - 34 : Disclosure regarding Transactions with Related Parties in terms of Accounting Standard - 18

Name of the related party	Nature of the relationship 31st December 2024	Nature of the relationship 31st March 2024	Nature of the relationship 31st	Nature of the relationship 31st
<b>A. Enterprises that directly or indirectly control/controlled by/under common control with, the reporting enterprise</b>				
Chandan Diagnostic Limited- PAN: AABCC9315J	Holding 67.99% of share capital	Holding 67.99% of share capital	Holding 67.99% of share capital	Holding 67.99% of share capital
Chandan Hospital Limited - PAN: AABCC9314K #	Common director	Common director	Holding 9.66% of share capital	Holding 9.66% of share capital
Indira Diagnostic Centre & Blood Bank Limited - PAN: AABCI0214L	Holding 100% of share capital	Holding 100% of share capital	Holding 100% of share capital	Holding 100% of share capital
Chandan Pharmacy Limited - PAN: AAHCC1459M	Holding 53.56% of share capital	Holding 53.56% of share capital	Holding 53.56% of share capital	Holding 53.56% of share capital
Chandan Institute Of Medical Sciences Limited - PAN: AAJCC1470E	Holding 17.58% of share capital	Holding 17.58% of share capital	Holding 17.58% of share capital	Holding 17.58% of share capital
Cendana Pharmaceuticals Private Limited - PAN: AAKCC1981P	Common director	Common director	Common director	Common director
Anaranta Holdings (I) Private Limited - PAN: AAHCA1540R	Common director	Common director	Common director	Common director
Chandan Singh Foundation - PAN: AAATC2478F	Common director and trustee	Common director and trustee	Common director and trustee	Common director and trustee
Healthrely Private Limited- PAN: AAGCH9438N*	Common director	Common director and trustee	Common director and trustee	Common director and trustee
Chandan Cancer Institute Limited- PAN: AALCC9159N*	Common director	-	-	-
Chandan Super Speciality Hospital Limited- PAN: AALCC1234A*	Common director	-	-	-
<b>B. Associates and joint ventures of the reporting enterprise including investing party and venturer of said associates and joint ventures</b>				
Dr Amar Singh - PAN: AGQPS3396H - DIN: 01066328	Managing director of company (MD)	Managing director of company (MD)	Managing director of company	(MD)
Aamta Singh - PAN: AWSPS3633M - DIN: 01089065	Director of company	Director of company	Director of company	Relative of director
Virendra Singh - PAN: AFSP6571B - DIN: 01069343	Director of company*	Director of company*	Relative of director	Relative of director
Vinay Lamba - PAN: AAXPL5673R - DIN: 01220153	Director of company	Director of company	Relative of director	Relative of director
Vijay Singh - PAN: ALPS1503P - DIN: 02779087*	Director of company	Director of company	Director of company	Director of company
Aasi Singh - PAN: FRPFS0695A - DIN: 06973633*	Director of company	Director of company	Director of company	Director of company
Anant Singh - PAN: AWSPS3852L - DIN: 00989364*	Director of company	Director of company	Director of company	Director of company
Rishi Bhushan Kalia - PAN: ALVPK6157A - DIN: 06074018*	Director of company	Director of company	Director of company	Director of company
Hari Shanker Dixit - PAN: AARPD6602Q - DIN: 02383137*	Director of company	Director of company	Director of company	Director of company
Sandeep Kumar saraswat - PAN: APGPS5745F - DIN: 08354660*	Director of company	Director of company	Director of company	Director of company
Rajeev Nair - PAN: AVFNS3350K	Key managerial personnel (CFO & Company secretary)	Key managerial personnel (CFO & Company secretary)	Key managerial personnel (CFO &	Company secretary)
Mohammad Mohsin Rizvi - PAN: AQXPR3628G	Relative of director	Relative of director	Relative of director	Relative of director
Anita Singh - PAN: ARVPS1208G	Relative of director	Relative of director	Relative of director	Relative of director
Vishal Lamba - PAN: ABULPL4208N	Relative of director	Relative of director	Relative of director	Relative of director
Ajai Singh - PAN: AHNPS7865B	Relative of director	Relative of director	Relative of director	Relative of director
Nisha Lamba - PAN: JATPL6545J	Relative of director	Relative of director	Relative of director	Relative of director
Pragya Singh - PAN: DJVPS5075J	Relative of KMP	Relative of KMP	Relative of KMP	Relative of KMP
Shivalini Singh - PAN: CURPS9141R	Relative of director	Relative of director	Relative of director	Relative of director
Vikash Lamba - PAN: ACLPL2389Q	Relative of director	Relative of director	Relative of director	Relative of director
Deepa Lamba - PAN: AAYPL1519B	Relative of director	Relative of director	Relative of director	Relative of director
Anshu Lamba - PAN: ABGFL8606C	Relative of director	Relative of director	Relative of director	Relative of director



# During the financial year 2023-24, the company divested its investments in certain subsidiaries and associates. As a result of these transactions, these entities are no longer classified as subsidiaries or associates in the company's financial statements.

\* During the financial year 2023-24, the individual ceased to serve as a director

a. Details of transactions with related parties and amounts receivable/(payable) as at the beginning and end of the year:

Name of related party	Nature of Transaction	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Aasthi Singh	Opening Balance Payable/(Receivable)	(0.00)	18.00	(0.07)	-
	Opening Balance (Advances)	-	-	(0.07)	-
	Dividend for the Year	1.05	0.70	-	0.39
	Advances	0.30	-	0.07	-
	Payment	(1.05)	(48.70)	(2.00)	(0.42)
	Payment of Advances	(0.22)	-	-	(0.07)
	Receipt	-	-	0.07	-
	Reimbursement	-	10.00	-	-
	Professional fee	-	20.00	20.00	-
	Closing Balance (Advances)	0.08	-	-	(0.07)
	Closing Balance Payable/(Receivable)	(0.00)	(0.00)	18.00	(0.07)
Dr Amar Singh	Opening Balance Payable/(Receivable)	17.59	11.52	0.96	2.01
	Opening Balance (Advances)	-	-	-	-
	Dividend for the Year	34.80	21.20	-	10.6
	Professional fee	-	-	0.88	-
	Bonus for the Year	-	14.00	-	-
	Salary	150.00	310.00	220.00	135
	Payment	(195.41)	(339.88)	(210.32)	(174.51)
	Reimbursement	(0.11)	0.75	-	27.86
	Advances	-	-	-	-
	Payment of Advances	-	-	-	-
	Closing Balance (Advances)	-	-	-	-
Closing Balance Payable/(Receivable)	6.86	17.59	11.52	0.96	
Anita Singh	Opening Balance Payable/(Receivable)	-	(0.00)	6.86	1.96
	Opening Balance (Advances)	-	-	-	-
	Salary	-	35.26	-	27.18
	Reimbursement	-	-	-	7.13
	Receipt	-	-	10.00	8.00
	Commission	-	-	6.60	-
	Gratuity	-	-	20.00	-
	Payment	-	(35.26)	(43.46)	(37.41)
	Advances	-	-	-	-
	Payment of Advances	-	-	-	-
	Closing Balance (Advances)	-	-	-	-
Closing Balance Payable/(Receivable)	-	(0.00)	(0.00)	6.86	
Anant Singh	Opening Balance Payable/(Receivable)	47.94	47.94	48.00	48.00
	Opening Balance (Advances)	-	-	-	-
	Salary	-	-	-	-
	Dividend for the Year	1.58	1.05	-	0.53
	Advance	-	-	-	0
	Payment	(1.58)	(1.05)	(0.06)	(0.53)
	Advances	-	-	-	36.15
	Payment of Advances	-	-	-	(36.15)
	Closing Balance (Advances)	-	-	-	-
	Closing Balance Payable/(Receivable)	47.94	47.94	47.94	48.00




Rishi Bhushan Kalia	Opening Balance Payable(Receivable)	24.56	24.00	24.00	24.00
	Opening Balance (Advances)	-	-	-	-
	Professional fee	27.00	43.85	46.10	44.9
	Reimbursement	5.17	3.68	-	0.78
	Dividend for the Year	2.33	-	-	-
	Payment	(34.81)	(46.97)	(46.10)	(45.68)
	Advances	-	-	-	-
	Payment of Advances	(5.00)	-	-	-
	Closing Balance (Advances)	(6.00)	-	-	-
	Closing Balance Payable(Receivable)	24.23	24.55	24.00	24.00
Hari Shanker Dixit	Opening Balance Payable(Receivable)	-	-	-	-
	Opening Balance (Advances)	-	-	-	-
	Advance	6.00	-	-	-
	Dividend for the Year	(6.00)	4.00	-	2
	Payment	-	(4.00)	-	(2.00)
	Advances	-	-	-	-
	Payment of Advances	-	-	-	-
	Closing Balance (Advances)	-	-	-	-
	Closing Balance Payable(Receivable)	-	-	-	-
	Asmita Singh	Opening Balance Payable(Receivable)	(3.07)	4.23	45.40
Opening Balance (Advances)		-	-	-	-
Dividend for the Year		2.43	1.82	-	0.81
Deposit		-	-	0.75	44
Reimbursement		4.27	-	4.32	7.66
Advance		-	-	-	-
Bonus for the Year		-	-	-	-
Salary		83.00	150.56	80.00	40.5
Payment		(68.92)	(159.48)	(106.24)	(51.01)
Advances		-	-	-	-
Payment of Advances	-	-	-	-	
Closing Balance (Advances)	(2.28)	(3.07)	4.33	45.40	
Closing Balance Payable(Receivable)	9.27	4.24	3.60	5.00	
Vinay Lamba	Opening Balance Payable(Receivable)	-	-	-	-
	Opening Balance (Advances)	-	-	-	-
	Viray Lamba(Shares)	15.84	-	-	-
	Payment	(49.70)	(107.42)	(77.36)	(49.32)
	Advance	-	-	-	1.96
	Reimbursement	0.05	-	-	8.81
	Dividend for the Year	21.39	15.85	-	7.924
	Bonus for the Year	-	10.00	-	29.2
	Salary	21.90	86.60	78.00	1.89
	Advances	-	-	-	(1.99)
Payment of Advances	-	-	-	-	
Closing Balance (Advances)	18.75	9.27	4.24	3.60	
Closing Balance Payable(Receivable)	-	-	-	-	
Vijay Singh	Opening Balance Payable(Receivable)	2.83	19.84	4.31	1.20
	Opening Balance (Advances)	89.84	-	-	-
	Opening Balance (Advances)	0.17	0.08	0.00	0.17
	Dividend for the Year	13.49	8.99	-	4.50
	Reimbursement	-0.25	-	-	8.25
	Advance	-	-	-	-
	Gratuity	-	-	19.94	-
	Payment	(46.67)	(30.05)	(19.31)	(31.23)
	Salary	33.75	3.75	15.00	21.60
	Advances	11.16	1.71	0.36	1.28
Payment of Advances	(11.57)	(1.63)	(0.27)	(1.45)	
Closing Balance (Advances)	(0.24)	0.17	0.09	0.09	
Closing Balance Vijay Singh(Shares)	89.84	-	-	-	
Closing Balance Payable(Receivable)	2.98	2.83	19.84	4.31	
Sandeep Kumar sarawat	Opening Balance Payable(Receivable)	-	-	-	-
	Dividend for the Year	4.2	3.08	-	1.54
	Payment	(4.16)	(3.08)	-	(1.54)
	Closing Balance Payable(Receivable)	-	-	-	-
	Opening Balance Payable(Receivable)	(14.06)	(6.87)	(14.02)	(13.27)
	Opening Balance (Advances)	(0.00)	(0.11)	(0.03)	(0.29)
	Dividend for the Year	-	2.47	-	1.24
	Salary	-	-	-	0.58
	Professional fee	-	-	-	8.58
	Gratuity	-	-	20.00	-
Payment	-	(10.86)	(11.85)	(11.14)	
Advances	-	0.11	0.03	0.61	
Payment of Advances	-	-	(0.10)	(0.35)	
Closing Balance (Advances)	(0.00)	(0.00)	(0.11)	(0.03)	
Closing Balance Payable(Receivable)	(14.06)	(14.06)	(14.02)	(14.02)	



Rajeev Nain	Opening Balance Payable(Receivable)	6.68	0.63	8.26	(3.36)	
	Opening Balance (Advances)	(6.90)	(1.41)	(0.00)	3.36	
	Dividend for the Year	1.91	0.24	-	-	
	Advance/Reimbursement	(4.05)	5.51	-	8.47	
	Chandan Hospital LTD	-	(45.27)	-	-	
	Gratuity	-	-	-	10.38	
	Professional fee	-	-	16.50	1.00	
	Payment	(42.37)	(3.78)	(24.12)	(35.24)	
	Salary	36.41	49.34	-	27.00	
	Advances	79.13	24.24	3.46	34.00	
	Payment of Advances	(74.73)	(28.73)	(4.86)	(37.36)	
	Closing Balance (Advances)	(1.50)	(5.90)	(1.41)	(0.00)	
Closing Balance Payable(Receivable)	(1.43)	6.68	0.63	8.26		
Ajai Singh	Opening Balance Payable(Receivable)	-	-	-	-	
	Dividend for the Year	1.50	1.00	-	0.50	
	Payment	(1.50)	(1.00)	-	(0.50)	
Nisha Lamba	Closing Balance Payable(Receivable)	-	-	-	-	
	Opening Balance Payable(Receivable)	6.00	6.00	6.00	6.00	
	Opening Balance (Advances)	-	(0.88)	-	-	
	Dividend for the Year	3.35	2.23	-	1.12	
	Salary	-	-	13.79	-	
	Receipt	-	-	-	-	
	Payment	(3.35)	(2.23)	(13.79)	(1.12)	
	Advances	-	0.88	-	-	
	Payment of Advances	-	-	(0.88)	-	
	Closing Balance (Advances)	-	-	(0.88)	-	
Closing Balance Payable(Receivable)	6.00	6.00	6.00	6.00		
Pragya Singh	Opening Balance Payable(Receivable)	-	-	-	-	
	Salary	-	14.19	-	-	
	Payment	-	(14.19)	-	-	
Shaivalini Singh	Closing Balance Payable(Receivable)	-	-	-	-	
	Opening Balance Payable(Receivable)	0.31	0.23	-	0.12	
	Payment	(0.31)	(0.23)	-	(0.12)	
Vikas Lamba	Closing Balance Payable(Receivable)	-	-	-	-	
	Opening Balance Payable(Receivable)	174.47	252.64	246.81	245.57	
	Opening Balance (Advances)	-	(0.07)	(1.88)	-	
	Dividend for the Year	7.50	5.00	-	2.50	
	Payment	(14.55)	(8.38)	(14.34)	(22.56)	
	Advance	-	-	(0.00)	0.00	
	Salary	-	-	12.00	13.98	
	Gratuity	-	-	8.08	-	
	Reimbursement	7.05	3.98	-	7.41	
	Receipt	-	1.23	-	-	
	Advances	7.05	5.21	8.32	9.39	
	Payment of Advances	(7.93)	(5.14)	(8.51)	(11.27)	
	Closing Balance (Advances)	(0.88)	-	(0.07)	(1.88)	
	Closing Balance Payable(Receivable)	174.47	174.47	252.64	246.81	
	Vishal Lamba	Opening Balance Payable(Receivable)	(0.21)	11.04	0.64	-
		Opening Balance (Advances)	0.00	0.00	(4.81)	-
Dividend for the Year		2.31	1.54	-	0.77	
Advance		-	-	-	0.60	
Loan		-	-	-	8.67	
Salary		-	-	9.00	-	
Gratuity		-	11.25	11.25	-	
Payment		(2.31)	(25.04)	(9.74)	(14.18)	
Reimbursement		-	1.00	-	4.47	
Advances		1.91	1.00	4.81	0.50	
Payment of Advances		(13.36)	(1.00)	-	(5.61)	
Closing Balance (Advances)		(11.47)	0.00	0.00	(4.81)	
Closing Balance Payable(Receivable)		(0.21)	(0.21)	11.04	0.53	
Deepa Lamba		Opening Balance Payable(Receivable)	-	-	-	-
	Dividend for the Year	1.38	0.92	-	0.46	
	Payment	(1.38)	(0.92)	-	(0.46)	
Closing Balance Payable(Receivable)	-	-	-	-		



Anshu Lamba	Opening Balance Payable(Receivable)	-	-	-	-	
	Salary	-	11.90	-	-	
	Dividend for the Year	3.00	2.00	-	1.00	
	Payment	(3.00)	(13.90)	-	(1.00)	
	Closing Balance Payable(Receivable)	-	-	-	-	
Chandan Hospital Limited	Opening Balance Payable(Receivable)	848.58	197.86	(4.69)	-	
	Opening Balance Investment in equity share capital	-	(286.17)	(85.85)	-	
	Receipt	1,390.60	2,757.18	272.86	612.53	
	Dividend Income	-	(42.93)	-	-	
	Sales	(495.03)	(311.69)	(244.13)	(218.79)	
	Share sales	-	286.17	296.16	-	
	Share purchase	-	-	(414.93)	(85.85)	
	Payment	(354.27)	(1,750.64)	-	(398.43)	
	Closing Balance Investment in equity share capital	-	-	(214.62)	(85.85)	
		Closing Balance Payable(Receivable)	1,390.88	849.58	24.04	(4.69)
		Opening Balance Payable(Receivable)	28.27	158.83	-	-
Chandan Institute of Medical Sciences Limited	Opening Balance Investment in equity share capital	(245.97)	(222.97)	(222.96)	-	
	Share sales	199.97	-	-	222.97	
	Share Purchase	-	(23.00)	-	(222.97)	
	Receipt	0.74	-	158.83	-	
	Payment	33.02	(132.56)	-	(222.95)	
	Closing Balance Investment in equity share capital	(48.00)	(245.97)	(222.95)	-	
		Closing Balance Payable(Receivable)	60.04	26.27	158.83	(222.95)
		Opening Balance Payable(Receivable)	2.92	565.96	59.04	-
Chandan Pharmacy Limited	Sales	(43.56)	(16.09)	(24.60)	(173.69)	
	Purchase	20.88	20.23	12.18	187.89	
	Receipt	47.41	-	486.55	127.88	
	Dividend Income	-	(23.35)	-	-	
	Share sales	-	-	-	-	
	Payment	(25.01)	(543.83)	-	(83.14)	
		Closing Balance Payable(Receivable)	2.64	2.92	533.16	59.04
		Opening Balance Payable(Receivable)	-	-	-	-
Chandan Singh Foundation	CSR	12.45	6.06	-	-	
	Payment	-	(6.06)	-	-	
		Closing Balance Payable(Receivable)	12.45	-	-	-
Chandan Diagnostic Limited	Opening Balance Payable(Receivable)	-	45.98	(58.04)	-	
	Share sales	-	-	-	37.00	
	Payment	0.32	(45.98)	(10.62)	(58.04)	
		Closing Balance Payable(Receivable)	0.32	-	(68.66)	(58.04)
Indra Diagnostic Centre & Blood Bank Limited	Opening Balance Payable(Receivable)	4.57	348.70	54.76	-	
	Sales	(282.27)	-	(7.51)	(9.51)	
	Share sales	-	-	-	-	
	Receipt	283.85	-	55.88	409.45	
	Payment	-	(344.13)	-	(345.18)	
		Closing Balance Payable(Receivable)	6.15	4.57	103.13	54.76
		Opening Balance Payable(Receivable)	4.57	-	-	-
Gendana Pharmaceuticals	Receipt	-	44.68	-	-	
	Payment	(140.21)	(44.68)	-	-	
	Cheque Issued But Not Cleared	(1.18)	0	1.18	-	
	Purchase	179.67	4.57	-	-	
		Closing Balance Payable(Receivable)	42.85	4.57	1.18	-
		Opening Balance Payable(Receivable)	-	-	-	-
Chandan Super Speciality Hospital Limited	Receipt	-	-	-	-	
	Payment	(8.99)	-	-	-	
	Sales	61.00	-	-	-	
		Closing Balance Payable(Receivable)	72.01	-	-	-
		Opening Balance Payable(Receivable)	0.20	-	(78.35)	(135.60)
Amaranita Holdings (I) Private Limited	Professional Fee	-	21.00	-	29.22	
	Commission	-	-	20.00	-	
	Dividend	78.88	58.43	-	29.22	
	Receipt	-	25.2	108.45	165.71	
	Payment	(78.88)	(104.43)	(50.11)	(166.96)	
		Closing Balance Payable(Receivable)	0.20	0.20	-	(78.35)



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to consolidated financial statements.

Note No. :- 35 : Analytical ratios

Particulars	consolidated figures as at the end of 31st Dec, 2024		consolidated figures as at the end of 31st March, 2024		consolidated figures as at the end of 31st March, 2023		consolidated figures for the year ended 31st March, 2022	
<b>Current Ratio</b>								
Total current assets	8,971.41	1.03	7,215.51	1.05	5,355.34	0.95	4,315.08	0.96
Total current liabilities	8,702.89		6,861.17		5,659.93		4,511.45	
<b>Debt-to- Equity Ratio</b>								
Total liabilities	5,192.32	0.96	4,201.27	1.02	2,135.50	0.78	1,658.17	0.69
Total shareholder's equity	5,430.99		4,109.07		2,729.89		2,393.08	
<b>Debt service coverage ratio</b>								
EBIT	2,655.55	0.75	2,406.73	0.74	732.44	0.46	54.92	0.05
Current debt obligation	3,533.33		3,244.43		1,577.78		1,149.03	
<b>Return on Equity (%)</b>								
PAT	1,614.92	33.83%	1,627.63	47.60%	336.81	13.15%	(110.90)	-4.64%
Average shareholder's equity	4,773.53		3,419.48		2,561.48		2,387.72	
<b>Inventory turnover ratio (in days)</b>								
365* Average inventory	910,479.73	54.37	514,239	29.12	299,875	21.91	231,236	19.34
Sales	16,747.47		17,659		13,689		11,956	
<b>Trade receivables turnover ratio (in days)</b>								
365* Average account receivables	1,210,710.48	87.36	917,999	66.91	956,054	92.60	953,122.54	87.89
Net credit sales	13,859.31		13,720		10,324		10,844	
<b>Trade payables turnover ratio (in days)</b>								
365* Average trade payable	1,185,025.43	72.0248845	1,028,981	76.19	1,123,081	114.20	804,881	75.16
Net credit purchase	16,453.00		13,506		9,834		10,709	
<b>Net capital turnover ratio</b>								
Sales	16,747.47	53.78	17,659	709.91	13,689	(54.65)	11,956	(68.86)
Average working capital	311.43		24.87		(250.48)		(173.64)	
<b>Net profit ratio (%)</b>								
PAT	1,614.92	9.64%	1,627.63	9.22%	336.81	2.46%	(110.90)	-0.93%
Sales	16,747.47		17,659.00		13,689.00		11,956.00	
<b>Return on Capital Employed (%)</b>								
EBIT	2,655.55	27.15%	2,407	35.04%	732	15.51%	55	1.34%
Average (Shareholder's equity + Current & Non current borrowings)	9,779.88		6,867.93		4,723.54		4,098.20	





Notes to consolidated financial statements.

Note No. :- 36 : Contingent liabilities and commitments

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024		Restated Consolidated figures for the year ended 31st March, 2024		Restated Consolidated figures for the year ended 31st March, 2023		Restated Consolidated figures for the year ended 31st March, 2022	
	No of cases	Amount	No of cases	Amount	No of cases	Amount	No of	Amount
<b>Claims against the company not acknowledged as debts</b>								
1) District consumer disputes redressal forum	13.00	62.48	11.00	64.98	11.00	75.18	11.00	75.18
2) State consumer disputes redressal commission	1.00	1.98	2.00	1.98	2.00	1.98	2.00	1.98
3) Labour court	3.00	12.54	6.00	28.52	5.00	28.41	5.00	28.41
4) District and session court	2.00	12.70	9.00	29.52	5.00	10.18	4.00	9.84
<b>Direct tax matters</b>	1.00	137.75	1.00	137.75	1.00	137.75	1.00	137.75
<b>Guarantees</b>								
Guarantee provided to the State Bank of India in relation to borrowings undertaken by Chandan Hospital Limited.	-	-	10.00	1,223.67	5.00	850.67	-	-
Guarantee provided to the HDFC Bank of India in relation to borrowings undertaken by Chandan Hospital Limited.	6.00	460.96	-	-	-	-	-	-
Guarantee provided to the State Bank of India in relation to borrowings undertaken by Chandan Pharmacy Limited.	-	-	1.00	227.76	1.00	159.37	-	-
Guarantee provided to the HDFC of India in relation to borrowings undertaken by Chandan Pharmacy Limited.	1.00	680.87	-	-	-	-	-	-
<b>Total...</b>	27.00	1,367.31	40.00	1,714.18	30.00	1,263.54	23.00	253.17



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

Note No. :- 36 : Segment reporting

**Primary segments - Business Segments**

The company primarily operates state-of-the-art laboratories providing comprehensive pathological investigations and radiology services. Other activities conducted by the company are ancillary to its main business and do not significantly impact the financial statements. Consequently, in accordance with Accounting Standard 17 on Segment Reporting, the company has identified a single reportable business segment: "Diagnostics Services." As a result, segment information has not been disclosed.

**Secondary segments - Geographical Segments**

The company operates primarily in india and there is no other significant geographical segment.



Chandan Healthcare Limited

U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.

(All amounts are in ₹ lakhs, unless otherwise stated)

Notes to restated consolidated financial statements.

Note No. :- 38 : CSR expenditure

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024	Restated Consolidated figures for the year ended 31st March, 2024	Restated Consolidated figures for the year ended 31st March, 2023	Restated Consolidated figures for the year ended 31st March, 2022
Gross amount required to be spent by the company during the year.	12.46	4.86	-	-
Gross amount spent by the company during the year.	-	6.06	-	-
Shortfall/(Excess)	12.46	(1.20)	-	-

a. Disclosure on nature of CSR activities undertaken by the companies

Particulars	Restated Consolidated figures for the nine months ended 31st December, 2024				
	Paid in cash	Paid via bank	Paid in kind	Payable	Total
Promoting education	-	-	-	-	-

Particulars	Restated Consolidated figures for the year ended 31st March, 2024				
	Paid in cash	Paid via bank	Paid in kind	Payable	Total
Promoting education	-	6.06	-	-	6.06

Particulars	Restated Consolidated figures for the year ended 31st March, 2023				
	Paid in cash	Paid via bank	Paid in kind	Payable	Total
Promoting education	-	-	-	-	-

Particulars	Restated Consolidated figures for the year ended 31st March, 2022				
	Paid in cash	Paid via bank	Paid in kind	Payable	Total
Promoting education	-	-	-	-	-



Chandan Healthcare Limited  
U85110UP2003PLC193493

Registered address :- Biotech Park, Sector G, Kursi road, Jankipuram, Lucknow, Uttar Pradesh, India, 226021.  
(All amounts are in ₹ nearest lakhs or decimals thereof, unless otherwise stated)

Notes to financial statements for the nine months ended 31st December, 2024

**Note No. :- 38 : Other statutory information**

In the opinion of the board of directors, the current assets, loans and advances have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the balance sheet.

Balances with trade receivables / trade payables and loans & advances are subject to confirmation.

Previous year's figures have been regrouped /rearranged wherever necessary to make them comparable with current year's figures.

The company does not have any benami property, where any proceeding has been initiated or pending against the company for holding any benami property.

The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956 during the financial year.

The company has not traded or invested in Crypto Currency or Virtual Currency during the financial year.

The company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period.

The company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries.

The company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with the understanding (whether recorded in writing or otherwise) that the company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (ultimate beneficiaries) or (b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

The company does not have any transaction to report that is not recorded in the books of accounts and that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

The company has not been declared as wilful defaulter by any bank or financial institution or other lender.

The company does not have any immovable property (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.

The company confirms that the quarterly returns or statements of current assets, filed with banks or financial institutions in relation to borrowings secured by current assets, are in agreement with the books of accounts.

